Protocol Title:  A Phase 1, Open -label, Multicenter Study Evaluating the Safety and Tolerability, 
Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating 
Intravitreal Doses of ICON -1 in Patients with Uveal Melanoma Who are Planned to Undergo 
Enucleation or Brachytherapy  
 
Protocol date: 05 September 2016  
Study ID: [REMOVED]  
 
 
 
 
 
CLINICAL STUDY PROTOCOL  
 
PROTOCOL TITLE:  A Phase 1, Open -label, Multicenter Study Evaluating 
the Safety and Tolerability , Biologic Activity, 
Pharmacodynamics, and Pharmacokinetics  of Single  
and Repeated  Escalating Intravitreal Doses  of ICON -1 
in Patients with Uveal  Melanoma  Who are Planned to 
Undergo Enucleation  or Brachytherapy  
PROTOCOL NUMBER:  IT-003 
PHASE OF DEVELOPMENT:  Phase [ADDRESS_754155] : human Immuno -conjugate  1 (ICON -1) 
INDICATION:  Uveal  Melanoma  
IND NUMBER:  102,472  
SPONSOR:  Iconic Therapeutics , Inc. 
[ADDRESS_754156] 
South San Francisco, CA [ZIP_CODE]  
DATE OF PROTOCOL:  Original: 17 March  2016  
Amendment  1: [ADDRESS_754157] of the trial, appropriate institutional review boards or 
independent ethics committees, or duly authorized representatives of the [LOCATION_002] Food and 
Drug Administration (FDA) or national r egulatory authority.  

Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 3 of 86 1 SPONSOR SIGNATURE [CONTACT_574669] (ICH) guidelines, Good Clinical Practices 
(GCPs), the Declaration of Helsinki, and complying w ith the obligations and 
requirements of the Sponsor as listed in Title 21 of the [LOCATION_002] Code of Federal 
Regulations.  
 
Approved by:  
  
___________________________________  _________________________  
Gabriela Burian, MD  
Chief Medical Officer  Date  
 
 
 
___________________________________  _________________________  
Debbi Kotlovker, MS 
Biostatistician  Date  
 
  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 4 of 86 2 PRINCIPAL INVESTIGAT OR SIGNATURE [CONTACT_44561]:  A Phase 1 , Open -label, Multicenter Study Evaluating the Safety 
and Tolerability , Biologic Activity, Pharmacodynamics, and 
Pharmacokinetics  of Single  and Repeated Escalating 
Intravitreal Doses  of ICON -1 in Patients with Uveal  Melanoma 
Who are Planned to Undergo Enucleation  or Brachytherapy  
 
Protocol Number:  IT-[ADDRESS_754158] ing the study as 
outlined herein in accordance with the current International Conference on Harmonisation (ICH) 
guidelines,  Good Clinical Practices (GCPs)  and the Declaration of Helsinki, and complying with 
the obligations and requirements of the Clinical Investigator and other requirements as listed in 
Title 21 of the [LOCATION_002] Code of Federal Regulations and other applicable regulations .  
I agree to provide the Sponsor with accurate financial information to allow the Sponsor to submit 
complete and accurate certification and disclosure statements as required by [CONTACT_106887].  
 
 
 
Principal Investigator‚Äôs Name (Printed)  
   
 
 
Principal Investigator‚Äôs Signature  
  [CONTACT_574670].  Clinical Study Protocol  
IT-[ADDRESS_754159] information may be updated by [CONTACT_574597] a protocol amendment.  
Sponsor:  
 Iconic Therapeutics, Inc.  
[ADDRESS_754160]  
South San Francisco, CA [ZIP_CODE]  
Phone: (650) 437 -1000  
 
Medical Monitor:  
 Wendy Murahashi , MD  
Medical Monitor  
Phone  : ([PHONE_11918]  
 
Sponsor‚Äôs Responsible Medical 
Officer:  
 Gabriela Burian, MD  
Chief Medical Officer  
Phone  : (650) 437 -1000  
 
 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 6 of 86 4 PROTOCOL SYNOPSIS  
Protocol Title  A Phase 1 , Open -label, Multicenter Study Evaluating the Safety and 
Tolerability , Biologic Activity, Pharmacodynamics, and 
Pharmacokinetics  of Single and Repeated  Escalating Intravitreal 
Doses  of ICON -1 in Patients with Uveal  Melanoma W ho are Planned 
to Undergo Enucl eation  or Brachytherapy  
Protocol Number  IT-003 
Study Phase  Phase 1 
Study Sites  Approximately 7-10 centers located in the U nited States  
Study Objectives  Primary Objective  
ÔÇ∑ To evaluate the safety  and tolerability  of single and repeated 
escalating i ntravitreal injections of ICON -1 administered  in 
patients wi th uveal  melanoma  who are planned to undergo  
enucleation  or brachytherapy . 
Secondary Objectives  
ÔÇ∑ To assess the pharmacokinetics and pharmacodynamic effect 
of ICON -1 in patients with uveal melanoma.  
ÔÇ∑ To describe preliminary evidence of  the biologic activity  of 
ICON -1 as determined by [CONTACT_574598], and tumor 
size 
Exploratory Objective  
ÔÇ∑ To explore the prognostic in dicato r of the genetic profile  of 
the tumor  in relation to Tissue Factor  expression and response 
to ICON -1 therapy .    
ÔÇ∑ To describe preliminary evidence of the biologic activity of 
ICON -[ADDRESS_754161] for which the selected treatment management 
plan is enucleation or brachytherapy may be screened for this study. 
Eligible p atients will be assigned to one of three cohorts  that will be 
enrolled consecutively :  
Cohort 1  (enucleation or brachytherapy) : Single dose of 0.3 mg 
(300 ¬µg/100 ¬µl) ICON -1, (n=2)   
Cohort 2  (enucleation or brachytherapy) : Two doses of 0.3 mg 
(300 ¬µg/100 ¬µl) ICON -1 each administered one week apart , 
(n=3)  
Cohort 3  (enucleation or brachytherapy ): Two doses of 0.6 mg 
(300 ¬µg/100 ¬µl + 300 ¬µg/ 100 ¬µl ) ICON -1 each administered 
one week apart , (n=5)   
Each dose level will be evaluated for clinical safety before escalating 
to the next cohort. Clinical and safety data will be reviewed by [CONTACT_574599]-003 Safet y Review Committee (SRC)  comprised of at least one  
participating Clinical Investigator and the Iconic T herapeutics 
internal Safety Management Committee. The following ocular 
adverse events (even if non -serious)  are considered A dverse Events 
of Special Interest (AESIs) , and will be reported  by [CONTACT_574600] : 
ÔÇ∑ Ocular in flammatory event of CTCAE Grade ‚â• 3  
ÔÇ∑ Vitreous or retinal hemorrhage event interfering with 
visualization of the tumor or retina of CTCAE Grade ‚â• 2  
ÔÇ∑ Any acute onset treatment -emergent vision -threatening 
condition as assessed by [CONTACT_574601] (DLT) events. An ocular DLT is defined  as 
an ocular inflammatory adverse event of 3+ or more severity or a 
grade [ADDRESS_754162]. If no patient s experience  a DLT in cohort 3, then cohort 3 will 
be considered the maxi mum administered dose (MA D). If on e patient 
experiences a DLT  in any cohort , an add itional patient will be 
enrolled and evaluated at that dose level. For cohorts 1 and 2, i f two 
or more patients experi ence a DLT  in the original cohort or the 
expanded cohort, then enrollment in that cohort will be suspended 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 8 of 86 and any subsequent cohorts will  not be enrolled . For cohort 3, if two 
or more patients experience a DLT in the original cohort or the 
expanded cohort , then enrollment in the cohort will be suspended and 
the IT -003 Safety Review Committee will examine  the safety data to 
determine if  chan ges are warranted.  
If an AESI  occurs while the patient is at the study center and requires 
clinical management, the patient will remain at the study center 
according to the Investigator‚Äôs judgment. The patient will be 
managed according to the routine treatment practices of the study 
center. The patient will complete all subsequent study visits.  
All AESI s, serious adverse events , patient discontinuations and 
pregnancy reports must be reported to Iconic Therapeutics within 24 
hours of the investigator learn ing of the event.  
ICON -1 will be administered on Day 0 for all cohorts, and in addition 
on Day 7 for cohorts 2 and 3 only. Patients will return to the study 
center on Day 1 for a safety follow -up visit (all cohorts) and [ADDRESS_754163] Day 7  (cohorts 2 and 3 on ly). All patients will return to the clinic 
for safety, clinical, and imaging assessments prior to the scheduled 
surgical procedure. Patients will have their planned Standard of Care 
surgical procedure (enucleation or brachytherapy ) as early as [ADDRESS_754164]-procedure for follow -up safety assessment s (and ocular  
assessments for brachytherapy patients)  and end of study visit .  
Safety will be evaluated by [CONTACT_574602], 
clinical laboratory tests ( serum chemistry, hematology,  coagulation , 
and anti -drug antibody levels (ADA) ), vital signs measurements, 
abbreviated physical examinations, slit -lamp biomicroscopy, 
intraocular pressure (IOP), and dilated ophthalmoscopy.  
Pharmacodynamic and biological activity will be measured by [CONTACT_574603], spectral -domain optical coherence tomography 
(sdOCT), color f undus photography (CFP), fluorescein angiography 
(FA), ophthalmic ultrasound, and optionally (according to 
investigator judgment) indocyanine green ( ICG) angiography and 
enhanced -depth imaging optical coherence tomography (EDI -OCT) . 
Pharmacokinetic (PK) and Pharmacodynamic (PD) markers will be 
evaluated by [CONTACT_574604] -1, 
serum cytokine levels, circulating tissue factor  (TF), 
immunophenotypi[INVESTIGATOR_007] , and circulating tumor DNA (CTDNA) .  
For enucleation patients:  immediately f ollowing the enucleation  
procedure , vitreous humor will be aspi[INVESTIGATOR_574569] -1 
and proteomic analysis of  TF and cytokine levels. Following the 
clinical site ‚Äôs standard of care pathology of the tumor, prepared slides 
and/or tumor block samples will be sent to a central laboratory  for the 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 9 of 86 study  for additional study -related pathology evaluation of th e tumor 
(including ICON -1 binding, TF expression, protease activating 
receptors 2 ( PAR2 ) expression, immune infiltrate , and alterations of 
the vasculature ), genetic  profiling , and Exome sequencing  of the 
tumor. Genetic profiling  of the tumor  previously performed with fine 
needle aspi[INVESTIGATOR_574570].    
For brachytherapy patients:   the plaque placement procedure and 
associated follow -up will be according to the standard of care at each 
site.  
Patients  (or their legally authorized representative) may choose to 
withdraw from the study for any reason at any time without prejudice.  
Study assessments for an Early Termination Visit should be 
conducted in the event a patient  discontinues from the study 
prematurely . 
Study Duration  Enrollment is anticipated to take approximately [ADDRESS_754165] meet all of the following criteria to be included in the 
study:  
1. Verbal and written informed consent obtained from the subject or 
the subject‚Äôs legal  representative (as applicable).  
2. Males or females of any race, ‚â•[ADDRESS_754166] (choroid  and/or ciliary body ) in the study 
eye. Patients with metastatic disease are eligible . 
4. Planned enucleation or brachytherapy for primary uveal 
melanoma in  the study e ye.  
5. If a woman of childbearing potential (WOCBP) (i.e., not 
postmenopausal for at least 2 years or not surgically sterile), must 
have a negative serum pregnancy test at Screeni ng, and must use 
adequate birth control if they have a  non-surgically sterile male 
sexual partner throughout the study. Adequate methods of birth 
control include hormonal contraceptives, intrauterine 
contraceptive device (IUD), condom with spermicide, 
contraceptive sponge with spermicide, diaphragm with 
spermicide and cervical cap with spermicide.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 10 of 86 Exclusion Criteria  
Patients  who meet any of the following criteria will be excluded from 
the study:  
1. Uvea l melanoma  in the study eye  originating in  the anterior uveal 
tract ( iris). 
2. Chronic u ncontrolled glaucoma or ocular hypertension in the 
study eye defined as an IOP >25mmHg regardless of concomitant 
treatment with IOP -lowering medications.  
3. Previous participation in an investigational study of ICON -1. 
4. Known seri ous allergy to fluorescein sodium or indocyanine 
green for injection in angiography.  
5. Use of two or more concomitant anticoagulant treatments  (direct 
thrombin inhibitor class of  drugs such as Coumadin (w arfarin ), 
Pradaxa  (dabigatran) , and Xarelto  (rivaroxa ban)). Aspi[INVESTIGATOR_574571]. For p atients receiving 
one chronic anticoagulant treatment (e.g., patients with a history 
of cardiovascular/cerebrovascular diseases [events] or 
hospi[INVESTIGATOR_574572]) , the p atient must have  
confirmation of stable clotting time using the appropriate test 
(Prothrombin Time (PT) , International Normalized Ratio (INR)  
(e.g., Coumadin), or activated partial thromboplastin time ( aPTT ) 
(e.g., Pradaxa) ) over the last 6 months from the patient‚Äôs treating 
physician . Some agents do not require  PT/INR/ aPTT monitoring  
(e.g., Eliquis (api[INVESTIGATOR_3822])) .  
6. Hereditary or chronic hemorrhagic or coagulopathy conditions 
(i.e., hemophilia).  
7. Use of any investigational product or device within [ADDRESS_754167]‚Äôs clinical safety  or 
to interfere with the interpretation of the study results, such as 
optic neuritis or atrophy (related to multiple sclerosis or other 
neurological disease), uveitis, or retinal vasculitis  or other 
inflammatory intraocular conditions in the study eye.  
9. Presence of any other concurrent medical condition, including 
mental illness or substance abuse, deemed by [CONTACT_574605] a subject‚Äôs ability to provide informed 
consent, comply with monthly study visits and assessments, or 
interfere with the interpretation of the study results.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754168] is human Immuno -conjugate 1 ( ICON -1). 
ICON -1 is a recombinant fusion protein  that targe ts and binds to the 
aberrantly expressed  Tissue F actor in retina l disease , tumors and 
supporting stroma (vasculature, infiltrating mononuclea r cells). It is a 
dimeric antibody -like protein  with a molecular weight of 157 kDa ; 
each monomer has two functional domains joined by a linker. The 
targeting domain of ICON -1 is a mutated FVIIa protein conjugated to 
an Fc effector moiety of a human IgG1 im muno globulin .   
ICON -1 is supplied in single -use glass vials containing 0.28 mL of a 
sterile solution of ICON -1 at a concentration of 3 mg/mL in 15 mM 
HEPES , 150 mM NaC l, 25 mM Arginine, pH 7.4 with 0.01% of 
Polysorbate -[ADDRESS_754169] Article 
Adm inistration  Patients will be enrolled in  one of three cohorts :  
ÔÇ∑ 0.3 mg (300  ¬µg/100  ¬µl) ICON -1 administered on Day 0  
ÔÇ∑ 0.3 mg (3 00 ¬µg/10 0 ¬µl) ICON -1 administered on Day 0 and 
Day 7  
ÔÇ∑ 0.6 mg (300  ¬µg/100  ¬µl + 300 ¬µg/100 ¬µl ) ICON -[ADDRESS_754170] -spectrum 
microbicide will be given prior to injection.   
IOP will be measured before and aft er each injection . For cohort 3, 
the second intravitreal injection will be administered the same day 
following stabilization of IOP to the pre -injection level (i.e., within 5 
mmHg of the pre -injection IOP) and a minimum of [ADDRESS_754171] injection.  
Study Endpoints  Primary Endpoints  
Safety  
ÔÇ∑ Occurrence of ocular and systemic serious adverse events  
and adverse events  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 12 of 86 ÔÇ∑ Changes in standard clinical laboratory tests (serum 
chemistry, hematology, coagulation ) and  ADA levels  
ÔÇ∑ Changes in vital signs , and physical and ophthalmic 
examinations  
Secondary Endpoints  
Pharmacokinetics and Pharmacodynamic Markers  
ÔÇ∑ Plasma  levels of ICON -1 following intravitreal injections of 
ICON -1  
ÔÇ∑ Change in  circulating TF levels and serum cytokine levels 
following intravitreal injections of  ICON -1 
ÔÇ∑ Characterization of immunophenotypi[INVESTIGATOR_574573]  
ÔÇ∑ Change in tumor size (thickness, volume) as assessed by 
[CONTACT_407203] s (CFP, FA, sdOCT, ultrasound , ICG 
angiography , EDI -OCT ) from baseline  
Exploratory Endpoints  
ÔÇ∑ Characterization of the genetic  profi le of the tumor (Type 1 
or Type  2), and associated changes in the tumor TF with 
ICON -1 treatment  
ÔÇ∑ Characterization of pathologic findings of the tumor (ICON -
1 staining of tumor structures, TF and PAR2 expression, 
characterization of the immune infiltrate, and alterations of 
the vasculature)   
ÔÇ∑ ICON -1 and proteomic analysis (TF and other cytokine 
levels) of the vitreous humor   
Statistical Analyses  All patients who receive ICON -1 will be considered evaluable and 
will be included in the analysis. This study is exploratory and its 
sample size is  not determined by [CONTACT_515633].  
There are no interim analyses planned; however, patient clinical and 
safety data will be examined on an ongoing basis to ensure patient 
safety and compliance with the dose escalation rules . 
 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754172] (ICON -1) ................................ ................................ ..... [ADDRESS_754173] Identification Numbers  ................................ ................................ .........................  45 
13.2  Enrollment and Method of Assigning Patients to Treatment Arms  ................................ .. 45 
14 STUDY PROCEDURES  ................................ ................................ ................................ ..............  46 
14.1  Visit 1 (All cohorts): Screening (Day -7 through 0)  ................................ ..........................  46 
14.2  Visit 2 (All cohorts): Baseline (Treatment Day 0)  ................................ ............................  47 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 14 of 86 14.3  Visit 3 (All cohorts): Day 1  ................................ ................................ ...............................  48 
14.4  Visit 4 (Cohorts 2 and 3 only): Treatment Day 7 (¬±2 days)  ................................ ..............  48 
14.5  Visit 5 (Cohorts 2 and 3 only): [ADDRESS_754174] Day 7 treatment  ................................ ..............  49 
14.6  Visit 6 (All Cohorts): Procedure Assessments (On or 1 day prior to Surgical 
Procedure day)  ................................ ................................ ................................ ...................  49 
14.7  Visit 7 (All Cohorts): End of Study: 30 days ¬±[ADDRESS_754175] (AESIs)  ................................ .....................  [ADDRESS_754176] Retention  ................................ ................................ ................................ ..... 74 
19 ADMINISTRATIVE CONSI DERATIONS  ................................ ................................ .................  75 
19.1  Confidentiality  ................................ ................................ ................................ ...................  75 
19.2  Amendments to the Protocol  ................................ ................................ .............................  75 
19.3  Protocol Deviations  ................................ ................................ ................................ ...........  75 
19.4  Study Reporting Requirements  ................................ ................................ .........................  76 
19.5  Financial Disclosure  ................................ ................................ ................................ ..........  76 
19.6 Investigator Responsibilities  ................................ ................................ .............................  76 
19.7  Clinical Trial Agreement  ................................ ................................ ................................ ... 76 
19.8  Policy for Publication and Presentation of Data  ................................ ................................  76 
20 REFERENCES  ................................ ................................ ................................ ..............................  77 
21 APPENDICES  ................................ ................................ ................................ ..............................  80 
21.1  Appendix A:  Study Flowchart and Assessments ‚Äì Cohort 1 (Patients Undergoing 
Enucleation or Brachytherapy)  ................................ ................................ ..........................  81 
21.2  Appendix B:  Study Flowchart and Assessments ‚Äì Cohorts 2 and 3 (Patients 
Undergoing Enucleation or Brachytherapy)  ................................ ................................ ...... [ADDRESS_754177] OF IN -TEXT TABLES  
Table 1:  Toxicology and Immunogenicity Studies of ICON -1 ................................ .......28 
Table 2:  Summary of Preclinical Data Showing Anti -cancer Activity of 
ICON -1 ................................ ................................ ................................ ...30 
Table 3:  CTCAE Grading  ................................ ................................ ................................ [ADDRESS_754178] OF IN -TEXT FIGU RES  
Figure 1: Signaling Pathways Involved in TF Expression  ................................ ............... 25 
Figure 2: Function of TF in Cancer Progression  ................................ .............................. 26 
Figure 3: Molecular Structure of ICON -1 ................................ ................................ ........ 27 
Figure 4: Study Design Schema  ................................ ................................ ....................... [ADDRESS_754179] hematocrit  
Hgb hemoglobin  
ICON -1 human Immuno -conjugate 1  (ICON -1) 
HIPAA  Health Insurance Portability and Accountability Act  
ICF informed consent form  
ICGA Indocyanine green  angiography  
ICH International Conference on Harmonisation  
IgG immunoglobulin G  
IHC immunohistochemistry  
INR International Normalized Ratio  
IOP intraocular pressure  
IRB Institutional Review Board  
IUD intrauterine contraceptive device  
IVT intravitreal  
kg kilogram  
LDH  lactic dehydrogenase  
Lin lineage markers  
MAb  monoclonal antibody  
MAD  maximum administered dose  
M-CSF macrophage colony -stimulating factor  
MCV  mean corpuscular volume  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MDSC  myeloid derived suppressor cell  
mg milligram  
mL milliliter  
MPV  mean platelet volume  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754180] -of-Care  
SRC  Safety Review Committee  
TAM  tumor -associated macrophage  
TCR  Tissue -Cross -Reactivity  
TF tissue factor  
USPC  uterine serous papi[INVESTIGATOR_574574] -bearing potential  
  
 
In this protocol, Sponsor duties refer to responsibilities that will be performed by [CONTACT_1034], 
the Sponsor‚Äôs designee or the Sponsor‚Äôs designated CRO. In this protocol, Investigator refers to 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 20 of 86 the Principal Investigator [INVESTIGATOR_022]/her designee who is respons ible for performing study 
evaluations.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754181]  
The protocol , Investigator‚Äô s Broc hure, informed consent form  (ICF) , advertisements to be used 
for patient recruitment, and any other written information provided to patients for this  study, 
including all consent forms translated to a language other than the native language of the clinical 
site must be approved by [CONTACT_737]‚Äôs Institutional Review Boar d (IRB)  or Ethics 
Committee (EC) before the study is initiated at a site . Docum entation of this approval must be 
maintained by [CONTACT_574606]  (or designee ) and must be made 
available during an inspection by [CONTACT_3133] ( FDA ) or other 
regulatory agency inspectors.  Prior to initiat ing the study, the Investigator will obtain writ ten 
confirmation that the IRB  is properly constituted and compliant with International Conference on 
Harmonisation ( ICH) and Good Clinical Practice (GCP) requirements, and all applicable laws 
and local regula tions.  
The study will not be initiated at your site until documentation confirming approval of the 
protocol, ICF, and any written materials supplied to the patient are received by [CONTACT_574607]. Approv al documentation from the IRB /EC should be signed by [CONTACT_1201] /EC 
chairperson or designee, identify the IRB /EC by [CONTACT_45972], refer to the study protocol by 
[CONTACT_29985] /or protocol number and version or date , identify documents reviewed, and include the 
date of the review and approval  or favora ble opi[INVESTIGATOR_574575] .   
Appropriate reports on the progress of the study will be made to the IRB /EC and to the Sponsor 
(or designee) by [CONTACT_574608], and in agree ment with policies of the IRB /EC. The Investigator must provide 
written documentation of the following to the Sponsor (or designee ): 
ÔÇ∑ IRB/EC periodic (e.g., semi -annually, annually) re -approval of the protocol as required 
by [CONTACT_779]‚Äôs IRB  
ÔÇ∑ IRB/EC approvals of any amendments to the protocol or revisions to the ICF  
ÔÇ∑ IRB/EC receipt of safety and SAE reports, as appropriate  
ÔÇ∑ Any additional submissions (including an end of study repor t) required by [CONTACT_779]‚Äôs 
IRB/EC. 
7.[ADDRESS_754182] of the Study  
This stu dy will be conducted in compliance with GCP as described in FDA regulations (21 CFR 
parts 50, 54, 56, and 312) , the ICH document ‚ÄúGuidance for Good Clinical Practice, E6 (R1) ,‚Äù 
and the principles of the World Medical Association Declaration of Helsinki ‚Äì Ethical Principles 
for Medical Research Involving Human Subjects, including all amendments and Notes of 
Clarification . The Investigator is expected  to comply with the requirements of the protocol , and 
will conduct  all aspects of this study in accordance wit h all national, state, and local laws or 
regulations . 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754183] Information and Consent  
Written informed consent in compliance with FDA regulations (21 CFR 50.25) , the ICH 
document ‚ÄúGuide line for Good Clinical Practice, E6 (R1),‚Äù and other applicable local r egulations 
shall be obtained from each patient prior to entering the study or performing any study related 
procedure . An ICF template will be provided by [CONTACT_1034]  (or designee ) to clinical sites. The 
ICF will be submitted by [CONTACT_574609]/EC for review and approval prior to 
the start of the study. If any modifications to the content are proposed or made by [CONTACT_779], the 
ICF should be reviewed by [CONTACT_1034] (or designee ) prior to IRB/EC submission.  
The investigator is responsible for obtaining written informed consent from each patient 
participating in  the study. If there are any revisions  to the ICF during the course of the study , all 
active participating  patients must  be re-consented using the revised ICF in a timely fashion.   
Informed con sent must be obtained from the patient before any study related screening activity 
or treatment is undertaken that is not part of routine care . This includes, but is not l imited to, the 
performance of diagnostic or therapeutic procedures and the administration of the first dose of 
the study treatment . All pertinent aspects of the study must be explained to the prospective 
patient and/or the patient‚Äôs legally authorized repr esentative before signing the ICF. The patient 
and/or patient‚Äôs legally authorized representative will be informed that participation is voluntary 
and he/she can withdraw from the study at any time. The patient and/or patient‚Äôs legally 
authorized represent ative will be allowed to read the IRB/EC approved ICF. Once the 
Investigator or designee is assured the patient /patient‚Äôs legally authorized representative  agrees 
to participate in the study, the patient/legally authorized representative will be asked to g ive 
consent by [CONTACT_12568] . The ICF must be signed and dated by [CONTACT_37410]‚Äôs 
legally authorized representative, and by [CONTACT_52223] , and witness (if required) . The Investigator shall provid e a copy of the signed and 
dated ICF to the patient/patient‚Äôs legally authorized representative. The original shall be 
maintained in the patient‚Äôs medical records at the site. This document should not be displayed or 
made accessible to any third party exce pt the Sponsor,  its designee or regulatory agency 
representatives.  
If a patient permanently revokes informed consent and declines further observation and/or 
contact , then this must be clearly documented in the patient‚Äôs chart and reco rding of further data 
will be discontinued.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 23 of 86 8 INTRODUCTION  
8.1 Background  
Ocular melanoma (OM) is the second most common primary malignant melanoma in adults and 
leads to significant mortality and ocular morbidity [1]. About 95% of OM tumors can be 
described as Uve al Melanoma (UM), which develop in the melanocytes (pi[INVESTIGATOR_482429]) of the 
eye and primarily affect the choroid, iris and ciliary body of the uveal tract [2,3]. Using data 
from the Surveillance, Epi[INVESTIGATOR_623], and End Results (SEER) program the mean age -adjusted 
incidence of UM in the US is estimated to be 5.1 per million . An estimated 2,000 new cases of 
UM are diagnosed each year (2,4). In Europe the rate of new cases ranges from over 2 per 
million in Spain and Italy to over 6 per million in northern European countries  [5,6]. 
Current Therapi[INVESTIGATOR_574576] -of-Care (SOC) for OM is currently radiation therapy  or surgical r emoval of the eye 
(enucleation ).  There are no chemotherapy agents or targeted biologics approved by [CONTACT_574610].  Small tumors (<10 mm in diameter and <2 mm in height) are often observed 
until growth is documented. Symptomatic patients wit h medium or large tumors usually receive 
some form of radiation, either plaque radiotherapy (brachytherapy) or proton beam radiation  [2]. 
However, th ese radioactive therapi[INVESTIGATOR_574577], cataracts, glaucoma and significant vision loss. For large tumors 
enucleation is usually performed. Thus, there is a need for treatment of OM that avoids the  loss 
of an eye or the acute and chronic complications of radiation, while still preserving sight.  
Neither radiation nor enucleation affects the rate at which metastatic disease occurs [7]. While 
local recurrence in the eye is rare, five - and ten -year rates of distant metastasis of [ADDRESS_754184] been reported [8] and nearly half of all ocular melanomas will eventually develop 
distant metastasis , primarily in the liver , with lung and bone marrow the other sites. Once 
metastases have occurred, median survival is between [ADDRESS_754185], approximately 
50 percen t of all patients will die of metastatic disease within 10 years following diagnosis, 
despi[INVESTIGATOR_574578], successful local treatment, and close follow -up [9]. 
There is an urgent need for new therapeutic strategies for OM that are not only less or non -
invasive, but that also have a potential to slow the onset of metastas es.  
Prognostic Markers in Uveal  Melanoma  
Proper assessment of the extent of disease and propensity for metastasis is one of the major 
challenges in the current management of UM.  For example, UM is not only a localized ocular 
disease; circulating  tumor  cells (C TCs) have been observed as early as initial diagnosis [10].  In 
uveal  melanoma patients, the presence of tyrosinase RNA in the peripheral blood was found to 
be associated with the stage of disease an d predicted disease progression in patients with early as 
well as advanced melanoma [11,12,13]. In fact, the presence of tyrosinase or MelanA /MART1 
transcripts is an independent prognostic factor in patients with high -risk primary UM [14,15,16]. 
However, as with cutaneous melanoma  [17], multiple markers will likely be needed to increase 
the sensitivity of tumor cell detection, i.e. micrometastasis, in UM. 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 24 of 86 The Molecular Pathogenesis of Uveal Melanoma  
Uveal melanoma harbors early activating mutations in GNAQ or GNA11 found in 80 percen t of 
primary uveal melanomas [18].  Mutations in BRCA1 -associated protein -1 (BAP1) and splicing 
factor 3B subunit 1 (SF3B1) occur later in tumor progression and are mutually exclusive [19]. 
Ciliary  body tumor location has also been associated with monos omy 3 and gains in 
chromosome 8 , both  molecular markers of poor prognosis [20]. 
Uveal Melanomas Classificat ion 
Type 1  Low Risk of Metastasis or Type 2 High Risk of Metastasis are based on gene expression 
profile. Genes that discriminate class 1 (low -risk) from class 2 (high -risk) include highl y 
significant clusters of down -regulated genes on chromosome 3 and up -regulated genes on 
chromosome 8q [21]. Tumors have begun to be classified as having low (class 1) or high (class 
2) metastatic potential, depending on the e xpression of 15 genes [22]. 
Why Target Tissue Factor in Uveal  Melanoma  
Tissue Factor is a 46kd 263 amino acid single chain transmembrane glycoprotein. Tissue Factor 
plays a key role in health and disease . In normal homeostasis it is involved in the initiation of 
coagulation via its external domain and mediation of pro -inflammatory pathways via extra and 
intracellular signaling . In tumor biology it has been show n to trigger angiogenesis, tumor growth 
and metastasis , and promote an inflammatory  immune environment (via extra - and intracellular 
signaling) . ‚Ä® 
Two studies support the role of TF in UM. Direct evidence comes from Walker et al who 
showed TF was expressed at elevated levels in cell lines of uveal melanoma compared with 
normal uveal melanocytes by [CONTACT_574611], RNAase protection 
and Reverse Transcription PCR [23].  In another study, Van Raamsdonk et al found that 83% of 
the 713 uveal melanomas they analyzed had somatic mutations in GNAQ or GNA11, both of 
which are genes coding for the alpha subunit of G prot eins. They concluded that GNAQ and 
GNA11 are activated in a MET -PI3K -dependent manner, and are significant contributors to the 
development of UM [18]. Activation of  the MET -P13K pathway has been shown to increase TF 
expression in cancer ( Figure 1) [24]. 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 25 of 86 Figure 1: Signaling Pathways Involved in TF Expression  
 
(Figure 1  from Han et al. Journal of Hematology & Oncology 2014,7:54)   
Molecular Basis for Tissue Factor Signaling in Tumorigenesis and Metastasis  
1) TF regulates tumor cell proliferation and apoptosis. The TF/Vll  complex initiates many of its 
activities by [CONTACT_574612] (PAR2) ( Figure 2). The TF/Vll/PAR2 
complex can lead to activation of enzymatic  pathways (PKC, MAPK, P13K) regulating cell 
proliferation as well as inhibition of apoptosis by [CONTACT_574613] 3  [25]. 
2) TF promotes tumor an giogenesis and metastasis . Blood vessels in tumor tissues are essential 
for tumor progression and neovasculatu re is a prerequisite for blood -borne metastasis. 
TF/FVIIa/PAR2 induces the production of proangiogenic factors (VEGF) and migration 
promoting fact ors such as fibroblast growth factor 2 (FGF2), cysteine -rich 61 (Cyr61), CXCL1 
and IL -8 [26]. TF exhibits its pro -metastatic characteristics in part by [CONTACT_574614] -coagulant 
cascade in the tumor microenvironment, including thrombin formation, fibrin generation and 
platelet activation. This fibrin -platelet ‚Äúclot‚Äù formation is essential for generating a shield around 
tumor cells to facilitate the spread of tumo r cells and the escape of newly formed 
micrometastasis  from natural killer (NK) cell -mediated cytolysis [27]. 

Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 26 of 86 Figure 2: Function of TF in Cancer Progression  
 
 
Immuno -oncology:  TF can modulate immune responses within the tumor microenvironment. 
Once thrombin is generated, it can directly cleave complement component C5 to produce C5a 
and C5b. C5a has a pro -tumor effect via recruiting myeloid derived suppressor cells to the tumor 
microenvironment, resulting in an immunosuppressive milieu [28]. 
Increased TF expression by [CONTACT_574615] a variety 
of chemokines, cytokines  and to the accumulation of Type 2 macrophage s (TAMs) within the 
tumor. Tumor -associated macrophages (TAMs) actively promote tumor growth by [CONTACT_574616] (MDSCs). Tumor 
associated macrophages (Type 2 macrophages) produce high levels of  IL-10, TGF -beta and low 
levels of IL -12. Type 1 macrophages produce low levels of IL -10 and high levels of IL -12.   
Myeloid derived suppressor cells (MDSCs) are characterized by [CONTACT_574617] T cells and NK cells  - a key m echanism of tumor defense. MDSCs originate from 
myeloid progenitor cells and are immature cells that do not differentiate into granulocytes, 
macrophages, or dendritic cells (DCs).  
Figure 2. Function of TF in cancer progression.  TF forms TF/FVIIa complex and subsequently induce PAR 
signaling us ing GPR alpha, beta, gamma (G protein coupled receptors). PKC is phosphorylated by [CONTACT_574618], which leads to p -PKC translocation. PAR can also induce MAPK and PI3K activation, both of which 
trigger pro -tumor effects, such as proliferation, angi ogenesis and metastasis. Binding to activator protein (AP) can 
also induce c -Jun up regulation and in turn promote tumor progression. Moreover, TF binding to ABP -280 leads 
to actin modulation, resulting in tumor cells metastasis. As TF binds to integrin re ceptor and enhances the ability 
of migration, in turn leading to tumor cell angiogenesis and migration (From Han et al. Journal of Hematology & 
Oncology 2014, 7:54) . 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754186]-negative or 
low, and lineage markers (Lin) (CD3, CD14, CD19, CD56) negative. Multiple tumor -derived 
factors secreted from the tumor and tumor stroma (tumor associated macrophages, fibroblasts 
and vascular endothelium) drive MDSC recruitment and different iation. These tumor - derived 
factors include granulocyte -macrophage colony -stimulating factor (GM -CSF), granulocyte 
colony -stimulating factor (G -SCF), macrophage colony -stimulating factor (M -CSF), IL -1ùõΩ, IL-6, 
VEGF, I L-13, IL -10, prostaglandin E2. Among t hese factors, GM -CSF and IL -[ADDRESS_754187] 
powerful in inducing MDSCs from bone marrow progenitors. GM -CSF is required for 
recruitment of MDSCs to the tumor microenvironment. Tumor -derived CXCR2 ligands (IL -8, 
CXCL1, CXCL2, CXCL5) also attract MDSCs to the tumor microenviro nment  [29]. 
ICON -1  
Iconic Therapeutics, Inc. has developed a therapeutic immunoprotein known as ICON -1 to target  
and bind  TF. ICON -1 is a  recombinant fusion protein , an antibody -like protein with a mo lecular 
weight of 157 kDa, that has two functional domains, one targeting and one effector domain 
joined by a linker  (Figure 3). The targeting moiety of ICON -1 is a mutated factor VIIa protein 
and the Fc portion from a human IgG1 immunoglobulin is unchanged and maintains its effector 
function . The mutated VIIa is defective as a clotting signal but retains its specific high affinit y 
for TF. When ICON -1 binds to TF expressed on the surface of cells, the Fc moiety is activated as 
it binds to the Fc receptor on NK cells, initiating cell -mediated cytotoxicity [30]. Secondary 
mechanisms of action that may be involved include complement activation and interference with 
TF int racellular signaling.  
Figure 3: Molecular Structure of ICON -[ADDRESS_754188] tumor growth and 
development. Early pre -clinical work demonstrated the ability of ICON -1 to cause antibody 
dependent cell mediated cytotoxicity of tumor target cells, and vascular endothelium. Other 
mech anisms under investigation include complement mediated cytotoxicity of targeted tissues 
and blockade of TF dependent internal signaling. The therapeutic potential of ICON -1 is derived 
via the FVIIa targeting moiety, I CON -1 binds to the TF expressed on the surface of endothelial 

Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 28 of 86 cells, tumor cells and tumor infiltrating macrophages interfering with TF‚Äôs intracellular signaling 
and their function of inducing angiogenesis and mediating inflammat ion. Secondly, the TF -
bound ICO N-1 molecule, through its Fc effector region, signals the immune system to release 
natural killer (NK) cells and initiate cell -mediated cytotoxicity towards the tumor and its 
supporting stroma (vascular endothelium and infiltrating inflammatory cells).  
8.2 Nonclinical Studies  
Several  in vitro  and in vivo  studies support the characterization of the nonclinical 
pharmacodynamic s, safety pharmacology, pharmacokinetics, and toxico logy of ICON -1 in 
models of TF overexpression.  
A summary of th e toxicology and immunoge nicity studies conducted with ICON -1 via 
intravenous, intravitreal and subcutaneous administration are listed in Table 1. The intravitreal 
administration animal studies tested bo th single and repeated doses of ICON -1.  
Table 1:  Toxicology  and Immunogenicity Studies of ICON -1 
Study Type  Animal 
Model  Number 
of 
Animals  Route  Dose  Duration  
GLP; Tissue Cross 
Reactivity  human  ‚â•3 in 
vitro  5, 30 Œºg/mL   
NA  
Exploratory  mini-pig  3 IV 3-24 Œºg/kg   
12 days  
Exploratory  mini-pig  3 IVT 510 Œºg  12 days  
GLP; Single dose , 
PK  mini-pig  24 IV 6, 20, 60 Œºg/kg   
8 days  
  
GLP; Single dose  rabbit  9 IVT 150 Œºg  8 days  
GLP; Repeat dose  mini-pig  [ADDRESS_754189] -level (NOAEL) were determined. Pharmacokinetics evaluation of 
ICON -1 after intravenous administration in the porcine species determined the half -life of ICON -
1 at 14.1 to 30.6 hours and the NOAEL of 60 Œºg/kg  [data on file, Iconic Therapeutics] . 
ICON -[ADDRESS_754190] on thrombin generation up to a concentration of 1 
micromolar  [data on fi le, Iconic Therapeutics] . 

Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754191] Tissue Cross -Reactivity (TCR) study was performed to determine if ICON -[ADDRESS_754192] with normal human tissues, 
when tested at the experimentally -determined optimal concentration (5 Œºg/mL) or at a [ADDRESS_754193] with normal tissue  [data 
on file, Iconic Therapeutics] . 
Single intravitreal ( IVT) administration of ICON -[ADDRESS_754194] immune response in anti -
drug antibodies in all animals, as early as 15 days after the drug administration.  
These nonclinical results indicated that a single IVT dose of up to 600 Œºg of ICON -1 was 
tolerable and safe in mini-pi[INVESTIGATOR_14107]. The mutated FVIIa present in the ICON -1 molecule has minimal 
thrombin generation activity. The ocular reactions observed with the repeated IVT dose in mini-
pi[INVESTIGATOR_574579] -drug antibody (ADA) response after sub cutaneous administration in dogs 
and monkeys, suggested a species -specific immune response most likely due to the heterologous 
nature of the human protein in the three different species.  
These results were the basis of and supported the initiation of a sin gle IVT ascending dose study 
of ICON -[ADDRESS_754195] that part of the mechanism of action of ICON -1 is due to cell -
dependent cytotoxicity. Cocco et al [ 30] examined the response of chemotherapy -resistant 
primary uterine serous papi[INVESTIGATOR_448553] (USPC) cell lines to ICON -1 treatment in 
chromium release assays. Using rituximab as a control , USPCs overexpressing TF were shown 
to be highly sensitive to ICON -1 as measured by [CONTACT_79371] -mediating killing (65.6% ¬± 3.7%; range 
57.5 - 77.0%, P< 0.001). In contrast, virtually no cytotoxicity against USPCs was observed in 
controls (controls = untreated, n o ICON -1; rituximab treatment).  
When the molecule was tested in animal models of carcinoma, murine ICON -1 (delivered by [CONTACT_574619]) was shown to be effective in SCID -Hu and full murine models against 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 30 of 86 cutaneous melanoma, uterine, prostate and tong ue carcinoma [ 31,32,33,34]. Adenoviral vector 
production of murine ICON -1 cause tumor regression in xenografts models.   
Table 2:  Summary of Preclinical Data Showing Anti -cancer Activity of ICON -1 
Year  Author  Type of cancer  
1999  Hu et al [ 31]  Tumor vasculature endothelial cells  
1999  Wang et al [ 35] Human melanoma cells  
2000  Hu and Garen [ 32] Human and mouse melanoma cells  
2001  Hu and Garen [ 33] Tumor vasculature endothelial cells and mouse 
prostate cancer cells  
2010  Hu and Li [ 34]  Human tongue cancer cells  
2010  Cocco et al [ 30] Uterine serous papi[INVESTIGATOR_10928]  
2010  Cocco et al [ 36] Adenocarcinoma and squamous cell carcinoma of 
cervix  
 
8.3 Clinical Experience with ICON -1 
In clinical studies conduc ted by [CONTACT_574620], more than  one hundred  (100) patients  have 
been administered ICON -[ADDRESS_754196]-in-human Phase 1 study  (IT-001) initiated in October 
2010 and completed in July 2012, evaluated administration o f single doses of ICON -1 in 18 
patients with choroidal neovascularization (CNV) due to  age-related macular degeneration (wet 
AMD). The study population included both treatment -na√Øve patients and patients previously 
treated w ith chronic anti -VEGF therapy. In an ongoing Phase 2 , randomized, double -masked, 
active -controlled study (IT -002) in pa tients with CNV secondary to AMD , [ADDRESS_754197] been 
enrolled.  
The Phase 1 s tudy (IT-001) was an open -label , single intravitreal dose,  dose-escalating design. 
There were no control groups in this study. Six patients each were enrolled in one of three 
different cohorts of ICON -1; 60 Œºg, 150 Œºg, and 300 Œºg . The three cohorts were enrolled 
sequentially employing a traditional 3+3 design. The planned maximum adminis tered  dose in 
this study was 300  Œºg ICON -1. The maximum tolerated dose (MTD) of ICON -1 would be 
identified as the maximum dose at which no more than 1 of 6 patients had a confirmed 
significant safety event  (or [ADDRESS_754198] dose contemplated in the p rotocol) . At the 
investigator‚Äôs discretion, treatment with bevacizumab (Avastin ¬Æ) or ranibizumab (Lucentis ¬Æ) 
therapy was allowed two weeks after injection of ICON -[ADDRESS_754199] frequently reported adverse events were ocular (conjunctival hemorrhage [n=5], 
vitreous floaters [n=3], conjunctival edema [n=3], and signs of macular degeneration [n=3]) and 
commo nly related to the injection procedure or the retinal signs of the underlying AMD. Only 
one adverse event, a case of vitritis in the 300 Œºg cohort was considered by [CONTACT_303811]. No retinal or choroidal abnormalities were no ted on clinical examination or 
angiographically. There were no systemic adverse events reported. No significant systemic levels 
of ICON -1 or antibodies to ICON -1 were detected.  Single dose administration of ICON -1 in the 
Phase 1 study demonstrated prelimin ary evidence of biologic activity and pharmacodynamic 
effec t relevant to wet AMD;  clinical improvement in BCVA , associated with a reduction in CRT 
(on OCT) and a decrease of CNV area of leakage (on FA)  in some patients .  
The ongoing Phase 2 study (IT -002) is the first study to examine administration of repeated 
intravitreal doses of ICON -1. Eighty eight (88)  patients ‚â•[ADDRESS_754200] the safety of repeated intravitr eal injections of 0.3 mg ICON -1 
administered as monotherapy or in combination with ranibizumab (Lucentis ¬Æ) compared to 
ranibizumab monotherapy , and to test proof of conc ept by [CONTACT_574621] . Patients will receive up to six (6 ) monthly 
intravitreal administrations of study treatment  and followed for safety  and efficacy  through one 
month following administration of  the last intravitreal treatment . Safety is evaluated by [CONTACT_574622], and changes in clinical laboratory tests, 
vital signs and ophthalmic evaluations. In addit ion, the pharmacokinetic and immunogenetic 
evaluation of the presence of ICON -[ADDRESS_754201], FA, fundus 
autofluorescence imaging ( FAF) and CFP.  
Eighty six (86)  patients received three or more doses  of ICON -1 alone, in combination with 
Lucenti s¬Æ, or Lucentis ¬Æ alone.  Thirteen  SAEs in nine patients  have been reported to date.  There 
are currently no ocular or non -ocular safety events that led to study unmasking. No ocular or 
non-ocular safety signals have emerged to date and the study continues to be conducted as 
planned.  
8.4 Study Rationale  
Uveal melano ma is a life -threatening and devastating  disease chara cterized  by [CONTACT_574623]. Data  from preclinical studies , and current a nd ongoing clinical 
studies in wet AMD (described above) support s investigating ICON -1 as a potential ly less 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 32 of 86 invasive therapeutic option  delaying the need for enucleation  as well as possibly prolonging the 
onset of metastases .  
Patients scheduled for enucleation or brachytherapy as treatment of uveal melanoma provide an 
opportunity to examine the clinical safety of intravitreal administration of ICON -1 within a 
tumor environment. Examini ng the excised tissue after enucleation  will allow c onfirmation of 
the extent of TF expression and whether intravitreally administered ICON -1 binds to TF 
expressed  on uveal melanoma tumor cells and supporting stroma (target engagement).  The short 
term biologic response of ICON -[ADDRESS_754202] time in patients with uveal melanoma and to provid e preliminary 
evidence of biologic activity in support of additional studies.   
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 33 of 86 9 STUDY O BJECTIVES  
9.1 Primary Objective  
The primary objective of this study is : 
ÔÇ∑ To evaluate the  safety and tolerability of single and repeated escalating intravitreal 
injections of ICON -1 administered  in pa tients with uveal  melanoma  who are planned to 
undergo enucleation  or brachytherapy . 
9.2 Secondary Objectives  
The secondary objectives of this study are:  
ÔÇ∑ To assess the pharmacokinetics and pharmacodynamic effect of ICON -1 in patients wi th 
uveal melanoma.  
ÔÇ∑ To describe preliminary evidence of the biological activity of ICON -1 as determined by 
[CONTACT_574624], and tumor size . 
9.3 Exploratory Objective  
ÔÇ∑ To explore the prognostic in dicator of  the genetic profile of the tumor  in relation to Tissue 
Factor  expression and response to ICON -1 therapy . 
ÔÇ∑ To describe preliminary evidence of the biological activity of ICON -[ADDRESS_754203] for which 
the selected treatment management plan is enucleatio n or brachytherapy  may be screened for this 
study. Eligible patients will be assigned to one of three cohorts that will be enrolled 
consecutively:  
Cohort 1  (enucleation or brachytherapy) : Single dose of 0.3 mg (300 ¬µg/100 ¬µl) ICON -1, 
(n=2)   
Cohort 2  (enucleation or brachytherapy) : Two doses of 0.3 mg (300 ¬µg/100 ¬µl) ICON -1 
each administered one week apart , (n=3)  
Cohort 3  (enucleation or brachytherapy ): Two doses of 0.6 mg (300 ¬µg/100 ¬µl + 300 ¬µg/ 
100 ¬µl) ICON -1 each administered one week apart , (n=5)   
Each dose level will be evaluated for clinical safety before escalating to the next cohort. Clinical 
and safety data will be reviewed by [CONTACT_214144] -003 Safet y Review Committee (SRC)  comprised of at 
least one  participating Clinical Investigator and the Iconic T herapeutics internal Safety 
Management Committee. The following ocular adverse events (even if non -serious)  are 
considered A dverse Events of Special Interest (AESIs) , and will be reported  by [CONTACT_574625] : 
ÔÇ∑ Ocular in flammatory event of CTCAE Grade ‚â• 3  
ÔÇ∑ Vitreous or retinal hemorrhage event interfering with visualization of the tumor or retina 
of CTCAE Grade ‚â• 2  
ÔÇ∑ Any acute onset treatment -emergent vision -threatening condition as assessed by [CONTACT_574626] 
(DLT) events. An ocular DLT is defined  as an ocular inflammatory adverse event of 3+ or more 
severity or a grade 2  or higher unexpected  vitreous or retinal hemorrhage  interferi ng with the 
visualization of the tumor or retina .   
If an AESI  occurs while the patient is at the study center and requires clinical management, the 
patient will remain at the study center according to the Investigator‚Äôs judgment. The patient will 
be manag ed according to the routine treatment practices of the study center. The patient will 
complete all subsequent study visits.  
All AESIs , serious adverse events, patient discontinuations and pregnancy reports must be 
reported to Iconic Therapeutics within 24  hours of the investigator learning of the event.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 35 of 86 ICON -1 will be administered on Day 0 for all cohorts, and in addition on Day 7 for cohorts 2 and 
3 only. Patients will return to the study center on Day 1 for a safety follow -up visit (all cohorts) 
and [ADDRESS_754204] Day 7  (cohorts 2 and 3 only). All patients will return to the clinic for safety, 
clinical, and imaging assessments prior to the scheduled surgical procedure.  Patients will have 
their planned surgical procedure (enucleation or brachytherapy  plaque pl acement ) as early as  [ADDRESS_754205]-procedure  for 
follow -up safety  assessments ( and ocular assessment s for brachytherapy patients) and end of 
study visit.  
Safety will be evaluated by [CONTACT_574627], clinical laboratory tests 
(serum chemistry, hematology, coagulation, and plasma anti-drug antibody levels (ADA)), vital 
signs measurements, abbreviated physical examinations, slit -lamp biomicroscopy, intraocular 
pressure  (IOP), and dilated ophthalmoscopy. Pharmacodynamic and biological activity will be 
measured by [CONTACT_574628], spectral -domain optical coherence tomography 
(sdOCT), color f undus photography (CFP), fluorescein angiography (FA), ophthalmic 
ultrasoun d, and optionally (according to investigator judgment) ICG angiography, and enhanced -
depth imaging optical coherence tomography (EDI -OCT) . Pharmacokinetic (PK) and 
Pharmacodynamic (PD) markers will be evaluated by [CONTACT_574629] -1, serum cytokine levels, circulating tissue factor (TF) , immunophenotypi[INVESTIGATOR_574580] (CTDNA) .  
For enucleation patients:  immediately f ollowing the enucleation  procedure , vitreous  humor 
will be aspi[INVESTIGATOR_574581] -1 and proteomic analysis of TF  and cytokine levels. 
Following the clinical site ‚Äôs standard of care pathology of the tumor, prepared slides and /or 
tumor block samples will be sent to a central laboratory  for additional study -related pathology 
evalu ation of the tumor (including ICON -1 binding,  TF and PAR2 expression, immune inf iltrate  
and alterations of the vasculature ), genetic profiling , and Exome sequencing  of the tumor. 
Genetic profiling of the tumor previously performed with fine needle aspi[INVESTIGATOR_574582] .     
For brachytherapy patients:  the plaque placement procedure and  associated follow -up will be 
according to the standard of care at each site .      
Patients  (or their legally authorized representative) may choose to withdraw from the study for 
any reason at any time without prejudice.  Study assessments for an Early Termination Visit 
should be conducted in the event a patient  discontinues from the study prema turely.  
  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 36 of 86 Figure 4: Study Design Schema  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Screening  (Day -7 to Day 0 ) and  
Baseline (Day 0)  
 
Intravitreal Injection(s)  
Sequential cohorts  
Cohort 1: 0.3 mg ICON -1 administered on Day 0  
Cohort 2: 0.3 mg ICON -1 administered on Day 0 and Day 7  
Cohort 3: 0.6 mg ICON -1 administered on Day 0 and Day 7  
(C1: n=2; C2: n=3; C3: n=5 ) 
 
 
Follow -up (From injection through  pre-procedure assessments  visit) and 
Scheduled Enucleation or Scheduled Brachytherapy  
DLT Review by  
[CONTACT_36792]-003 Safety Review Committee  
Review data through pre -procedure assessments visit in each cohort.  
0 DLTs in a cohort  
Escalate to the next cohort  
(as applicable)  
 1 DLT in a cohort  
Enroll additional patient in 
cohort  
 ‚â• 2 DLTs in a cohort  
Do not escalate to next cohort 
(as applicable)  
End of Study  (30 days after surgical procedure ) 0 additional DLTs  
Escalate to the next cohort  
(as applicable)   ‚â• 2 DLTs  
in original or expanded cohort  
Do not escalate to next cohort (as 
applicable)  DLT Review by  
[CONTACT_36792]-[ADDRESS_754206] time in patients with 
uveal melanoma. The starting dose of ICON -1 (300 ¬µg/100 ¬µl)  is the maximum dose 
administered in the Phase 1  single IVT administration  study , and the  ongoing Phase 2  repeated 
IVT administration  study in patients with CNV secondary to AMD . As this dose has been 
administered to approximately sixty ( 60) patients and  found to be well tolerated to date, a cohort 
of two patients which may be expanded to thre e patients is thought to be sufficient to make a 
determination to escalate to the subsequent higher dose level of two doses of 0.3 mg ( 300 ¬µg/100 
¬µl) ICON -1 administered one week apart .  The cohort size is increased  (cohort 2; n=3, cohort 3; 
n=5), as the dose and volume is escalated  in subsequent cohorts .  Each of these cohorts may be 
expanded by [CONTACT_574630] a DLT. A toxicity rate of one third or less in a cohort is 
within the accepted clinically observed toxicity standards  to establ ish a preliminary safety profile 
of ICON -1 administered in patients with uveal melanoma  and to support additional studies.  In 
this study, the maximum administered dose will not exceed 0.6 mg ( 300 ¬µg/100 ¬µl + 300 ¬µg/100 
¬µl) ICON -1. 
Pharmacodynami c and biolo gic activity markers are utilized to explore preliminary evidence of 
activity with respect to target engagement (ICON -1 binding to TF in the tumor) as measured by 
[CONTACT_574631],  assessment of 
immune infiltrate in the tumor,  measurement of TF  and PAR2  dependent cytokines/chemokines 
in blood, TF and cytokine levels in vitreous humor, and changes in tumor size and volume as 
well as changes in BCVA by [CONTACT_63365].  Ophthalmic ultrasound is utilized to assess and measure 
changes in the size of the ocular tumor. Ophthalmic imaging including sdOCT, EDI-OCT, FA, 
ICGA, and C FP are utilized for measuring and evaluating  changes in vasculature , in the 
anatomic layers of the re tina, choroid, and ocul ar tumor  and the associated pathology of the 
lesions ( such as exudation) .  
The study duration, including a  one to two week  dosing period  prior to a scheduled enucleation 
or plaque placement procedure is considered an adequate period to assess sa fety, PK an d 
preliminary pharmacodynamic and bio logic activity without delaying or interfering with standa rd 
of care treatment for uveal melanoma . 
10.[ADDRESS_754207] , ophthalmic ultrasound, CFP, FA, and ICG angiography . Ophthalmic  imaging 
modalities are routine assessments and are appropriate for documenting clinical findings of the 
retina, choroid, the ocular tumor and their vascularization at baseline and changes  across the 
duration of the study for comparison.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 39 of 86 11 STUDY POPULATION  
11.1 Target Population  
The target population for this study is men and women  age 18 years and o lder with a diagnosis of 
primary uveal melanoma  involving the choroidal and/or ciliary body  who are scheduled to 
undergo a standard o f care enucleation procedure  or brachytherapy .   
11.[ADDRESS_754208] meet all of the following criteria to be included in the study:  
1. Verbal and written infor med consent obtained from the subject or the subject‚Äôs legal 
representative (as applicable).  
2. Males or females of any race, ‚â•[ADDRESS_754209] (choroid 
and/or ciliary body)  in the study eye . Patients with metastatic disease are eligible . 
4. Plann ed enucleation or brachytherapy for primary uveal melanoma in the study eye . 
5. If a woman of childbearing potential (WOCBP) (i.e., not postmenopausal for at least 2 years 
or not surgically ste rile), must have a negative serum pregnancy test at Screening, and must 
use ad equate birth control if they have a non-surgically sterile male sexual partner 
throughout the study. Adequate methods of birth control include hormonal contraceptives, 
intrauteri ne contraceptive device (IUD), condom with spermicide, contraceptive sponge with 
spermicide, diaphragm with spermicide and cervical cap with spermicide.  
11.3 Exclusion Criteria  
Patients  who meet any of the following criteria will be excluded from the study:  
1. Uveal melanoma in the study eye originating in  the anterior uveal tract (iris).  
2. Chronic u ncontrolled glaucoma or ocular hypertension in the study eye defined as an 
IOP >25mmHg regardless of concomitant treatment with IOP -lowering medications.  
3. Previous par ticipation in an investigational study of ICON -1. 
4. Known serious allergy to fluorescein sodium indocyanine green for injection in 
angiography.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 40 of 86 5. Use of two or more concomitant anticoagulant treatments (direct thrombin inhibitor 
class of drugs such as Coumadi n (warfarin), Pradaxa (dabigatran), and Xa relto 
(rivaroxaban)). A spi[INVESTIGATOR_574583]. For patients 
receiving one chronic anticoagulant treatment (e.g., patients with a history of 
cardiovascular/cerebrovascular diseases [ events] or hospi[INVESTIGATOR_574584]), the pati ent must have confirmation of stable clotting time using the 
appropriate test (Prothrombin Time (PT), International Normalized Ratio (INR) (e.g., 
Coumadin), or activated partial thromboplastin tim e (aPTT) (e.g., Pradaxa)) over the 
last 6 months from the patient‚Äôs treating physician. Some agents do not require 
PT/INR/aPTT monitoring (e.g., Eliquis (api[INVESTIGATOR_3822])) .  
6. Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia).  
7. Use of a ny investigational product or device within [ADDRESS_754210]‚Äôs clinical safety  or to interfere with the interpretation of 
the study results, such as optic neuritis or atrophy (related to multiple sclerosis or 
other neurological disease), uveitis, or retinal vasculitis  or other inflammatory 
intraocular conditions in the study eye . 
9. Presence of any other concurrent medical condition, including mental illness or 
substance abuse, deemed by [CONTACT_101367] a subject‚Äôs 
ability to provide informed consent, comply with monthly study visits a nd 
assessments, or interfere with the interpretation of the study results.  
10. Woman who is pregnant or lactating.  
11.[ADDRESS_754211] ( ICON -1) 
The investigational product is human Immuno -conjugate 1 ( ICON -1). ICON -1 is a recombinant 
fusion protein  that tar gets and binds to the aberrantly expressed  Tissu e Factor (TF) . It is a 
dimeric antibody -like protein; each monomer has two functional domains joined by a linker. The 
molecular weight is [ADDRESS_754212] Article Administration  
Patie nts will be enrolled in one of three cohorts :  
ÔÇ∑ 0.3 mg (300  ¬µg/100  ¬µl) ICON -1 administered on Day 0  
ÔÇ∑ 0.3 mg (3 00 ¬µg/10 0 ¬µl) ICON -1 administered on Day 0 and Day 7  
ÔÇ∑ 0.6 mg (300  ¬µg/100  ¬µl + 300 ¬µg/100 ¬µl ) ICON -[ADDRESS_754213] -spectrum microbicide w ill be given prior to injection .   
IOP will be measured before and after each in travitreal  injection .  
For Cohort 3,  the second intravitreal injection  will be administered the same day following 
stabilization of IOP to the pre -injection level (i.e., within 5 mmHg of the pre -injection IOP) and 
a minimum of [ADDRESS_754214] injection.   
12.2 Study Drug Packaging, Labeling  and Sto rage  
ICON -1 will be provided by [CONTACT_574632] -use glass vials containing 0.28 
mL of a sterile solution of ICON -1 at a concentration of 3 mg /mL in 15 mM HEPES, 150 mM 
NaCl, 25 mM Arginine, pH 7.4 with 0.01% of Polysorbate -80 and 5 mM  CaCl 2.  
Vials of ICON -1 will be shipped frozen on dry ice and should be stored frozen at ‚â§ -60¬∫C  until 
just before use.  Temporary storage is permitted at -20¬∫C for up to [ADDRESS_754215] dose tested 
was 0.3 mg ICON -1 administered by [CONTACT_63385] , and repeated doses up to 6 monthly 
doses per patient were found to be well tolerated in all patients to date. A maximum tolerated 
dose was not determined in the phase 1 study. In the phase 2 clinical study 300 ¬µg/100 ¬µl ICON -
1 is being administered intrav itreally followed by 0.5 mg/50 ¬µl  ranibizumab  after 30 minutes, a 
total injection volume of 150 ¬µl. A total injection volume of 200  ¬µl for cohort 3 is supported by a 
preclinical study in mini -pi[INVESTIGATOR_574585] 600 ¬µg ICON -1 were administered as tw o 
doses of 300 ¬µg/100 ¬µl each , two days apart (see Section 8.1 for information regarding the 
preclinical, Phase 1 and Phase 2 studies) .  
12.4 Criteria for Dose -Escalation  and Stoppi[INVESTIGATOR_574586]:  
Cohort 1 (enucleatio n or brachytherapy) : Single dose of 0.3 mg (300 ¬µg/100 ¬µl) ICON -1, 
(n=2)   
Cohort 2  (enucleation or brach ytherapy) : Two  doses of 0.3 mg (300 ¬µg/100 ¬µl) ICON -1 
each administered one week apart , (n=3)  
Cohort 3  (enucleation or brachytherapy ): Two  doses of 0.6 mg (300 ¬µg/100 ¬µl + 300 ¬µg/ 
100 ¬µl) ICON -1 each administered one week apart , (n=5)   
Each dose level wi ll be evaluated for clinical safety before escalating to the next cohort. Clinical 
and safety data will be reviewed by [CONTACT_214144] -[ADDRESS_754216] 
one participating Clinical Investigator and the Icon ic Therapeutics internal Safety Management 
Committee. Patients will be evaluated for the occurrence of ocular Dose Limiting Toxicity 
(DLT) events. An ocular DLT is defined as an ocular inflammatory adverse event of 3+ or more 
severity or a grade [ADDRESS_754217]. 
If no patients experience a DLT  in cohort 3 , then cohort 3 will be considered the maximum 
administered  dose (MA D).  
If one patient experiences a DLT  in any cohort , an additional patient will be enrolled and 
evaluated at that dose level.  
For cohorts [ADDRESS_754218] be stored in a secure location with limited 
access restricted to authorized  study personnel  only. 
All vials of study drug will be recorded on a Drug Accountability Log accounting for all vials 
received, administered, not used, and destroyed. Drug Accountability will be performed by a 
Study Monitor during site visits. Once reconci led, study drug will be returned to the sponsor or 
destroyed at the site , as directed by [CONTACT_456] . If the study drug is to be destroyed at the site, i t 
is the Investigator‚Äôs responsibility to ensure arrangements have been made for appropriate 
destructio n according to applicable regulations, guidelines and procedures. Appropriate records 
of the destruction must be maintained.  
12.7 Prior and Concomitant Therapy  
All medications (prescription, over -the-counter (OTC) and herbal)  and nutritional supplements  
taken b y a subject from 30 days prior to Screenin g through the completion of the study  will be 
recorded . Changes in the dosing and/or  frequency of concomitant medication must be captured 
with new start and stop dates indicating the previou s and current doses/freq uencies . 
Use of two or more concomitant anticoagulant treatments (direct thrombin inhibitor class of 
drugs such as Coumadin (warfarin), Pradaxa (dabigatran), and Xarelto (rivaroxaban)) is 
prohibited. Aspi[INVESTIGATOR_574587]. Concomitant 
treatment with  one chronic anticoagulant (e.g., patients with a history of 
cardiovascular/cerebrovascular diseases [events] or hospi[INVESTIGATOR_574572]) is not 
prohibited . 
Use of treatment for concomitant metastatic  disease is allowed during the study.  
Use of topi[INVESTIGATOR_510315] -glaucoma medications is allowed during the study.  
Use of any investigational product or  device within [ADDRESS_754219] the Medical Monitor.  
12.8 Other Study  Supplies  
Additional supplies for administering study treatment intravitreal injections will include 1-cc 
tuberculin syringes, 5-micron 19 -gauge x 1 -1/[ADDRESS_754220] the Medical Monitor at  Iconic 
Therapeutics to confirm availability in the cohort . 
The Sponsor, Investigator, research staff and participants will know the treatment that is being 
administered as well as the cohort  assignment. Cohort 1 (single dose of 0.3 mg ICON -1) will be 
enrolled fir st, followed by [CONTACT_9084] 2 (two  doses of 0.3 mg ICON -1 administered one week apart), 
and then cohort 3  (two doses of 0.6 mg ICON -1 administered one week apart). Clinical and 
safety  data will be reviewed by [CONTACT_214144] -[ADDRESS_754221] completed their pre -procedure safety assessment visit  before enrolling patients into 
subsequ ent cohorts .   
 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 46 of 86 14 STUDY PROCEDURES  
The Study Flowchart and Assessments is presented in Section 21.1 (Appendix A). A detailed 
accounting of the assessments performed at each study visit is presented below.   An ICF must be 
signed and dated by [CONTACT_574633] ‚Äôs legally authorized representative, the person who 
conducted the informed consent discussion, and witness (if required) before any Screening 
assessments or treatment is undertaken that is not part of routine care.  The Screening Number 
should be a ssigned to the patient after informed consent is obtained.  
The protocol -specified procedures for a given study visit may be split across 2 days within the 
visit-specific  window  (if applicable) ; however,  for each visit all BCVA , ophthalmic exams  and 
imagin g must be performed on the same day and cannot be split across 2 or more days.  
14.1 Visit 1  (All cohorts ): Screening  (Day -7 through  0) 
Screening must take place within 7 days prior to  the intravitreal injection on Day 0  (Baseline 
Visit ). Patients  will undergo Screening assessments  to determine if they are eligible to enroll in 
the study. If there is study drug available at the clinical site, Screening assessments to confirm 
eligibility may be performed on Day 0, prior to any intravitreal injection  and any additional 
baseline specific assessments.  
The following procedures will be performed  at Screening : 
ÔÇ∑ Obtain written informed conse nt 
ÔÇ∑ Obtain d emographic data  
ÔÇ∑ Obtain m edical and ocular history including surgical and medication history . Prior and 
concomitant medications taken within the last 30 days will be recorded.  
ÔÇ∑ Vital signs  
ÔÇ∑ Blood samples for clinical laboratory tests (serum chemistry, hematology and 
coagulation) , prior to injection of Fluorescein and ICG dye  (as applicable)  
ÔÇ∑ Blood s ample for anti -drug antibody levels , prior to injection of Fluorescein and ICG dye 
(as applicable)  
ÔÇ∑ Blood sample for serum pregnancy test (women of child bearing potential only) , prior to 
injection of Fluorescein and ICG dye (as applicable)  
ÔÇ∑ Abbreviated phys ical examination including height and weight  
ÔÇ∑ Perform the following ophthalmic procedures:  
o Best-corrected visual acuity  by [CONTACT_63365] -like charts  (both eyes)  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 47 of 86 o Slit lamp biomicroscopy  (both eyes)  
o IOP (both eyes)  
o Dilated ophthalmoscopy  (both eyes ) 
o Color fundus photography  (both eyes ) 
o sdOCT  (study eye only)  
o EDI-OCT optional according to investigator judgment (study eye only)  
o Ophthalmic ultrasound (study eye only)  
o Fluorescein angiography  (both eyes ) 
o ICG angiography optional according to investigator judgment (both  eyes)  
14.2 Visit 2  (All cohorts ): Baseline (Treatment Day 0)   
Baseline assessments will be completed on Day 0. The following procedures will be performed : 
ÔÇ∑ Vital signs  
ÔÇ∑ Perform the following ophthalmic procedures:  
o Best-corrected visual acuity  by [CONTACT_63365]  (both eyes)  
o Slit lamp biomicroscopy  (both eyes)  
o IOP; cohorts 1 and 2 : pre-injection  (both eyes ) and post injection (study eye only ), 
cohort 3 : pre-injection (both eyes) and post each injection (study eye only)  
o Dilated ophthalmoscopy  (study eye only ) 
ÔÇ∑ Blood  sample (pre-injection and 4 hours ¬±1 hour after dose administration . For cohort 3, 
after the second injection ) for pharmacodynamic assessment  
ÔÇ∑ Blood samples (pre-injection and 4 hours  ¬±1 hour  after dose administration . For cohort 3, 
after the second injection ) for pharmacokinetic assessment  
ÔÇ∑ Administration of intravitreal  injection (s)  
ÔÇ∑ Assessment of adverse events  
ÔÇ∑ Record concomitant medications  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 48 of 86 ÔÇ∑ Instruct patients to contact [CONTACT_574634], sensitive to light, painful, or develops a change in vision.  
14.3 Visit 3  (All cohorts ): Day 1  
The following procedu res will be performed at Day 1 : 
ÔÇ∑ Vital signs  
ÔÇ∑ Perform the following ophthalmic procedures:  
o Best-corrected  visual acuity  by [CONTACT_63365]  (study eye  only) 
o Slit lamp biomicroscopy  (study eye  only) 
o IOP (study eye  only) 
ÔÇ∑ Blood sample for pharmacodynamic assessment  
ÔÇ∑ Blood sample for  pharmacokinetic assessment  
ÔÇ∑ Assessment of adverse events  
ÔÇ∑ Record concomitant medication  
14.4 Visit 4  (Cohorts 2 and 3  only): Treatment Day  7 (¬±2 days ) 
The following procedures will be performed at Day 7 : 
ÔÇ∑ Vital signs  
ÔÇ∑ Perform the following ophthalmic procedures,  prior to dose administration:  
o Best-corrected visual acuity by [CONTACT_63365] (both eyes)  
o Slit lamp biomicroscopy (both eyes)  
o IOP; cohort 2:  pre-injection (both eyes) and post injection (study eye only), 
cohort  3: pre-injection (both eyes) and post each injection (study eye only)  
o Dilated ophthalmoscopy (study eye only)  
o sdOCT (study eye only)  
o EDI-OCT optional according to investigator judgment  (study eye only)  
o Ophthalmic ultrasound (study eye only)   
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 49 of 86 ÔÇ∑ Blood samples for clinical laboratory tests (serum chemistry, hematology and 
coagulation)  
ÔÇ∑ Blood samples (pre -injection and 4 hours ¬±1 hour after dose administration. For cohort 3, 
after the second i njection) for pharmacodynamic assessment  
ÔÇ∑ Blood samples (pre -injection and 4 hours ¬±1 hour after dose administration. For cohort 3, 
after the second injection) for pharmacokinetic assessment  
ÔÇ∑ Administration of intravitreal injection(s)  
ÔÇ∑ Assessment of advers e events  
ÔÇ∑ Record concomitant medication  
ÔÇ∑ Instruct patients to contact [CONTACT_574635], sensitive to light, painful, or develops a change in vision.  
14.5 Visit 5 (Cohorts 2 and 3  only): [ADDRESS_754222] Day 7 treatment  
The following proced ures will be performed on the day after Day 7 treatment : 
ÔÇ∑ Vital signs  
ÔÇ∑ Perform the following ophthalmic procedures:  
o Best-corrected  visual acuity  by [CONTACT_63365]  (study  eye) 
o Slit lamp biomicroscopy  (study  eye) 
o IOP (study  eye) 
ÔÇ∑ Blood sample for pharmacodynamic assessment  
ÔÇ∑ Blood sample for pharmacokinetic assessment  
ÔÇ∑ Assessment  of adverse events  
ÔÇ∑ Record concomitant medication  
14.6 Visit 6  (All Cohorts ): Procedure Assessments  (On or 1 day prior to Surgical 
Procedure  day) 
The following procedu res will be performed on or 1 day prior to the Su rgical Procedure  day: 
ÔÇ∑ Vital signs  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 50 of 86 ÔÇ∑ Perform the following ophthalmic procedures , (prior to Surgical  Procedu re): 
o Best-corrected visual acuity by [CONTACT_63365] (both eyes)  
o Slit lamp biomicroscopy (both eyes)  
o IOP (both e yes) 
o Dilated ophthalmoscopy ( both eyes) 
o Color fundus photography  (both eyes)  
o sdOCT (study eye only)  
o EDI-OCT optional according to investigator judgment (study eye only)  
o Ophthalmic ultrasound (study eye only)  
o Fluorescein  angiography  (both eyes)  
o ICG angiogra phy optional according to investigator judgment ( both eyes ) 
ÔÇ∑ Blood samples for clinical laboratory tests (serum chemistry, hematology, and 
coagulation)  
ÔÇ∑ Blood sample for pharmacodynamic assessment  
ÔÇ∑ Assessment of adverse events  
ÔÇ∑ Record concomitant medication  
Surgical Procedure will be performe d ‚â•[ADDRESS_754223] injection : 
The surgical  procedure  (enucleation or plaque placement)  is scheduled independent of this 
study according to standard of care clinical management of uveal melanoma per patient‚Äôs 
treating physician and is not a study procedure.  
For Patients Undergoing Enucleation  Only : After enucleation , the following samples will be 
obtained:  
ÔÇ∑ Vitreous humor  aspi[INVESTIGATOR_574588] -1 and proteomic analysis  
ÔÇ∑ A subset of pathology mounted slides and/or tumo r block samples from the globe and 
tumor will be provided by [CONTACT_574636].  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 51 of 86 14.7 Visit 7  (All Cohorts ): End of Study: 30 days ¬±[ADDRESS_754224] Surgical Procedure  
The followi ng proced ures will be performed 30 ¬±5 days after the Surgical Procedure : 
ÔÇ∑ Vital signs  
ÔÇ∑ Perform the following ophthalmic procedures  (brachytherapy patients only) : 
o Best-corrected visual acuity by [CONTACT_63365] (both eyes)  
o Slit lamp biomicroscopy (both eyes)  
o IOP (both eyes)  
o Dilated ophthalmoscopy ( both eyes ) 
o Color fundus photography ( both eyes ) 
o sdOCT (study eye only)  
o Ophthalmic ultrasound (study eye only)  
ÔÇ∑ Abbreviated physical examination  
ÔÇ∑ Blood samples for clinical laboratory tests (serum chemistry, hematology, and 
coagulation)  
ÔÇ∑ Blood sample for anti -drug antibody levels  
ÔÇ∑ Blood sample for serum pregnancy test (women of child bearing potential only)  
ÔÇ∑ Assessment of adverse events  
ÔÇ∑ Record concomitant medication  
If follow -up is needed after the End of Study visit, it should occur as a post -study unscheduled 
visit at the discretion of the Investigator. Patients with an ongoing SAE at this visit will be 
followed until the event is resolved or stabilized as described in Section 15.22.10  
14.8 Early Termination  Visit  
Patients  who discontinue study drug or withdraw from the study prematurely will undergo an 
Early Termination  (ET) visit . At this visit,  the following will be performed:  
ÔÇ∑ Vital signs  
ÔÇ∑ Blood samples for clinical laboratory tests (serum chemistry, hematology, and 
coagulation) , prior to injection of Fluorescein and ICG dye (as applicable)  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 52 of 86 ÔÇ∑ Blood sample for anti -drug antibody levels , prior to injection of Fluorescein and ICG dye 
(as applicab le) 
ÔÇ∑ Blood sample for serum pregnancy test (women of child bearing potential only) , prior to 
injection of Fluorescein and ICG dye (as applicable)  
ÔÇ∑ Blood sample for pharmacodynamic assessment (collect only if Day [ADDRESS_754225] 
Day 7 treatment  PD samples wer e not collected following injection on Day 0 or Day 7) , 
prior to injection of Fluorescein and ICG dye (as applicable)  
ÔÇ∑ Blood sample for pharmacokinetic assessment (collect only if Day [ADDRESS_754226] Day 7 
treatment  PK samples were not collected following i njection on Day 0 or Day 7) , prior to 
injection of Fluorescein and ICG dye (as applicable)  
ÔÇ∑ Abbreviated physical examination  
ÔÇ∑ Perform the following ophthalmic procedures  (note: ocular assessments are performed 
only if early termination occurs prior to Surgic al Procedure ): 
o Best-corrected  visual acuity  by [CONTACT_63365]  (both eyes)  
o Slit lamp biomicroscopy  (both eyes)  
o IOP (both eyes)  
o Dilated ophthalmoscopy  (both eyes ) 
o Color fundus photography  (both eyes ) 
o sdOCT  (study eye only ) 
o EDI-OCT optional according to investigator judgment (study eye only)  
o Ophthalmic ultrasound (study eye only)  
o Fluorescein angiography  (both eyes ) 
o ICG angiography optional according to investigator judgment (both eyes)  
ÔÇ∑ Assessment of adverse events  
ÔÇ∑ Record concomitant medication  
If follow up is needed a fter the early Termination visit, it should occur as a post -study 
unscheduled visit at the discretion of the Investigator. Patients  with an ongoing SAE at this visit 
will be followed until the event is resolved or stabilized as described in Section 15.22.10 .  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 53 of 86 14.9 Unscheduled Visits  
Unscheduled visits may be necessary due to AEs or other reasons. The Investigator may examin e 
a patient  as often as is medic ally necessary while the patient  is enrolled in the study. Any follow -
up that is performed to monitor patient safety should be recorded  as an Unscheduled Visit . 
14.10  Patient  Withdrawal from Treatment or Study  
14.10.1  Handling of Withdrawals  
Patients  (or their legally authorized repre sentative) may choose to withdraw from the study for 
any reason at any time without prejudice . The study assessments for the Early Terminati on Visit 
should be conducted in the event a patient  discontinues from the study prematurely.  If a patient  
withdraws from the study, he or she may not reenter the study.  
The Princi pal Investigator or the Sponsor may withdraw a patient  from the study for any of the 
following reasons:  
ÔÇ∑ Adverse event  
ÔÇ∑ Prohibited therapy ( patient  requires concomitant medication or a medical procedure 
prohibited by [CONTACT_760] ) 
ÔÇ∑ Subject noncompliance ( patient  does not adhere to the requirements specified by [CONTACT_12695] ) 
ÔÇ∑ Subject improper entry ( patient  was enrolled in the study but did not meet the  eligibility 
criteria ) 
ÔÇ∑ Subject withdrawal of consent  
ÔÇ∑ Pregnancy ( patient  becomes pregnant ) 
ÔÇ∑ Lost to follow -up 
ÔÇ∑ Death  
At the time of withdrawal, the Principal  Investigator [INVESTIGATOR_574589]. When a patient  is withdrawn from the study for any reason, the reason(s) for 
withdrawal will be recorded in the eCRF. For any patient  who withdraws due to an AE, the 
reason for withdrawal must be recorded as an AE and not any other reason. Whenever possible, 
all patient s who withdraw from the study prematurely will undergo assessments listed for the 
Early Termination  visit.  
If a patient  fails to return for a scheduled visit, it is the responsibility of the Principal Investigator 
[INVESTIGATOR_574590].  If a patient  cannot be contact[CONTACT_213229] [ADDRESS_754227] a known reason for discontinuation (e.g., 
withdrawal of consent or an AE), the reason for discontinuation will be recorded as ‚Äúlost to 
follow -up‚Äù. The date that the certified letter was mailed will be considered the date of study 
withdrawal.  
In the event of a patient  death during the study, the date of death (a s listed on the death 
certificate) will be used as the date of study withdrawal.  
It is vital to obtain follow -up data on any patient  who is withdrawn due to an AE. In such cases, 
every effort must be made to undertake protocol -specified safety follow -up pr ocedures.  
The Medical Monitor should be notified promptly when a patient  is withdrawn.  
The Sponsor may terminate  the study at any time for clinical or administrative reasons and may 
discontinue participation by [CONTACT_574637].  
14.10.[ADDRESS_754228] injection may  be replaced.  
14.10.3  Sponsor or Regulatory Agency Termination of the Study  
Although the Sponsor intends to complete the study, the right is reserved to discontinue the study 
at any time for clinical or administrative reasons, or if required by [CONTACT_17196].  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 55 of 86 15 STUDY A SSESSMENTS  
This section describes the study assessment procedures. Se e Study Flowchart and Assessments  
(Section 21.1 - Appendix A) for timing of each assessment.  
15.1 Informed Consent  
Each site will be required to obtain IRB/EC approval of the ICF. Before any study specific 
procedures are performed, the investigator o r designee will provide the subject or the subject‚Äôs 
legally authorized representative with a copy of the current IRB/EC approved ICF and allow 
adequate time for review and t he opportunity to ask any questions regarding the study and/or 
ICF. The Investigator should answer all questions to the best of his ability and to the satisfaction 
of the subject or the subject‚Äôs legally authorized representative before performing any stud y visit 
assessments.  The ICF should be signed and dated by [CONTACT_35323]‚Äôs legally authorized 
representative, the Investigator or his designee, and witness (where applicable) before any study 
specific procedures are performed.  
The consenting proce ss must b e conducted in accordance with  ICH GCP and local regulatory 
and/or IRB/EC requirements. A copy of the signed and dated ICF should be given to the subject 
or the subject‚Äôs legally authorized representative and a copy should be maintained in the 
subject‚Äôs medical records. The consenting process should be documented in the subject‚Äôs source 
record including the names of persons participating in the discussions and a brief summary of 
what was discussed including questions and responses.  
If the protocol is amended or new safety information becomes available, and revisions are 
required to the ICF, the subject or subject‚Äôs legally authorized representative will be required to 
sign the updated IRB/EC approved ICF.  
If a subject or subject‚Äôs legally authorized  representative withdraws consent at any time the date 
and time and details of the discussion should be recorded in the subject‚Äô s source record along 
with the names of the persons participating in the discussion.   
15.[ADDRESS_754229] study visit  
will be recorded . The patient ‚Äôs source record should incl ude start and stop dates, dose, route, 
frequency, and indication.  
15.6 Vital Signs  
Vital signs should be taken when the patient  is adequately rested (after the patient  has been 
resting in a seated position for at least 5 minutes). Vital signs measurements include blood 
pressure (systolic and diastolic in millimeter of mercury (mmHg)), heart rate (beats/minute), 
respi[INVESTIGATOR_697] (breaths/minute), and temperature (‚ó¶C).  
15.7 Abbreviated Physical Examination  
Abbreviated physical examination should include at a minimum assessments of general 
appearance, cardiovascular, respi[INVESTIGATOR_696], neck/HEENT  (head, eyes, ears, nose and throat), and 
dermatologic. Height and weight will be measured  at Screening only. Additional assessments 
should be c ompleted at the judgment of the Investigator.  
15.[ADDRESS_754230]-corrected visual acuity ( BCVA ) will be measured for each eye, pre -treatment prior to 
dilating eyes, using standard Early T reatment Diabetic Retinopathy Study (ETDRS) -like retro -
illuminated charts. BCVA will be recorded as the total letter score in each eye.  
Visual acuity testing  will be performed by [CONTACT_574638] , and should occur before any 
examination requiring contact [CONTACT_222199]. In order to provide standardization and well -
controlled measurements of BCVA during the study, all measurements at a single site must be 
consistently done using the same lighting conditions, correction, chart type, and measurement 
procedure for an individual  patient throughout the study.  
A study specific refraction and BCVA testing protocol will be provided in a separate BCVA 
testing and imaging procedures manual.  
15.[ADDRESS_754231] clinical practice. The patient will be seated during the examination. This 
procedure should  be conducted in the same manner for all patients and will include an 
assessment of each of the following as normal or abnormal:  
ÔÇ∑ Eyelids  
ÔÇ∑ Conjunctiva  
ÔÇ∑ Cornea  
ÔÇ∑ Anterior chamber  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 57 of 86 ÔÇ∑ Iris 
ÔÇ∑ Lens  
All abnormal findings that are clinically significant will be described. A change from normal to 
abnormal for any biomicroscopic variable will be considered clinically significant.  
15.[ADDRESS_754232] 
tonometry  (e.g. Goldmann  Applanation, Tono -Pen). It is recommended that the same instrument 
be used  throughout the duration of the study for each patient. At injection visits, IOP will be 
measured in both eyes before the injection by [CONTACT_1746] , and in the study eye only 
after intravitreal  injection  (in Cohort 3, IOP will be measured in the study eye following each of 
the two injections) . Measurements will be recorded in mmHg (e.g., 19 mmHg).  At the [ADDRESS_754233] examination, and continue to be performed in accordance with the 
manufacturer‚Äôs specifications until the last patient  at the site has exited the study.   
15.11  Dilated Ophthalmoscopy  
A dilated fundus examination of the study eye will be performed pre-treatment  in all patients  by 
[CONTACT_574639] . The following will be observed for the presence of 
abno rmalities:  
ÔÇ∑ Vitreous body  
ÔÇ∑ Peripheral Retina  
ÔÇ∑ Macula  
ÔÇ∑ Choroid  
ÔÇ∑ Optic nerve  
All abnormal findings that are clinically significant will be described. A change from normal to 
abnormal for any ophthalmoscopic variable will be considered clinically significant.  
15.12  Color Fundus Photography  
Color fundus photography ( CFP) for each eye will be performed to assess the retina and 
characteristics of the ocular tumor  in the study eye . Color fundus photographs will be obtained 
using a dig ital fundus camera and will be perform ed by [CONTACT_574640] . 
For detailed instructions regarding performance of CFP , please refer to the BCVA testing and 
imaging procedures  manual  provided separately.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 58 of 86 15.13  Ophthalmic Ultrasound  
Ophthalmic ultrasound of the study eye will be performed to assess  and measure (depth, width,  
and height) the ocular tumor  from the external surface of the sclera . Ophthalmic ultrasound  will 
be performed by [CONTACT_574639] . 
For detailed instructions regarding collection of ultrasound measurements, please refer to the 
BCVA testing and imaging procedures  manual  provided separately.  
15.14  Spectral -Domain Optical Coherence Tomography  
Spectral -domain optical coherence tomography (sdOCT)  imaging of the study eye will be 
performed to measure and assess cross -sectional images of the anatomic layers of the retina , the 
ocular tumor  and associated pathological changes . sdOCT will be performed pre -treatment 
during  visits in which ICON -[ADDRESS_754234] imaging will be obtained using a 
Spectral -Domain (High Definition) OCT device by [CONTACT_574639]. 
Preferably the same machine will be used for initial and follow -up assessments of each patient.  
For detailed inst ructions regarding collection of sdOCT imaging, please refer to the BCVA 
testing and imaging procedures  manual  provided separately.  
15.15  Enhanced Depth Imaging Optical Coherence Tomography  
Enhanced depth optical coherence tomography (EDI -OCT) imaging of the stu dy eye will be 
performed optionally, according to investigator judgment , to evaluate the structural changes of 
the choroid in the area of the tumor.  
EDI-OCT will be performed pre -treatment during visits in which ICON -[ADDRESS_754235] imaging, please refer to the BCVA 
testing and imaging procedures  manual  provided separately.  
15.16  Fluorescein Angiography  
Fluorescein angiography (FA) imaging (after intravenous a dministration of Fluorescein dye) for 
each eye  will be performed to examine the circulation of the retina and characteristics of the 
ocular tumor in study eye according to standard FA image capture protocol. FA images will be 
obtained using a digital came ra by [CONTACT_574639] . 
For detailed instructions regarding collection of FA images, please refer to the BCVA testing and 
imaging procedures  manual  provided separately.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 59 of 86 15.17  ICG  Angiography  
Indocyanine green angio graphy  (ICGA)  imaging (after  intravenous administration of 
Indocyanine G reen dye) for each eye  will be performed optionally, according to investigator 
judgment , to examine the blood vessels and connective tissue of the choroid  and the ocular tumor  
in the study eye . ICGA images will b e obtained using an infra -red sensitive  camera  by 
[CONTACT_574639].  
For detailed instructions regarding collection ICG imaging , please refer to the BCVA testing and 
imaging procedures  manual  provided separately.  
15.[ADDRESS_754236] es for routine clinical laboratory tests  and immunogenicity tests  will be collected. 
The minimum tests to be performed includ e:  
ÔÇ∑ Hematology ( complete blood count  including white blood cell [ WBC ] count, WBC 
differen tial, red blood cell [RBC] count, hematocrit [Hct], hemoglobin  [Hgb], mean 
corpuscular volume [ MCV ], mean corpuscular hemoglobin [ MCH ], mean corpuscular 
hemoglobin concentration  [MCHC], red cell distribution width [RDW], platelet count , 
mean platelet volum e [MPV],  and C-reactive protein  [CRP ])  
ÔÇ∑ Serum chemistry profile (albumin, alkaline phosphatase, alanine aminotransferase [ ALT ], 
aspartate aminotransferase [ AST ], blood urea nitrogen [BUN], calcium, serum chloride, 
carbon dioxide [CO2], creatinine , BUN /creatinine ratio, creatinine clearance [CrCl] using 
Cockcroft -Gault formula, creatine  phosphokinase [ CPK ], direct and total bilirubin, 
triglycerides, gamma -glutamyl transferase [GGT] , globulin, glucose, lactic 
dehydrogen ase [LDH], phosphorus , potassium, s odium, total cholesterol, total protein, 
uric acid ) 
ÔÇ∑ Serum pregnancy test for women of child bearing potential  
ÔÇ∑ Coagulation  (PT, INR , fibrinogen, and activated partial thromboplastin time [ aPTT ]) 
ÔÇ∑ Immunogenicity (plasma anti-drug antibody [ ADA ]) 
Any abnormal test results determined to be clinically significant by [CONTACT_574641], the 
value returns to baseline or to within normal limits, or the Investigato r determines that the 
abnormal value is no longer clinically significant. Clinical laboratory results should be initialed 
and dated by [CONTACT_574642]. Clini cally significant laboratory results should be recorded as an AE , 
preferably as a diagnosis where possible . 
Blood samples will be obtained to measure systemic levels of anti -drug antibodies. Blood 
samples for measurement of anti -drug antibodies will be dra wn before the first intravitreal 
injection at Screening/Baseline before the intravitreal injection and at Week 2 , Week 8 and the 
Early Termination visit (as applicable ).  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754237] had a total hyste rectomy to be 
considered  not of child bearing potential.  
It is the investigator‚Äôs responsibility to perform clinical laboratory assessments more frequently 
if clinically indicated.  
Hematology, serum chemistry, coagulation, and serum pregnancy tests  will b e performed by a 
central  laboratory . ADA samples will be batch analyzed by a central bioanalytical laboratory. 
For detailed instructions regarding collection, storage and handling of clinical laboratory and 
immunogenicity  samples, please refer to the Labor atory  Manual provided separately.  
15.19  Pharmacokinetic and Pharmacodynamic Markers  
Blood samples for PK (plasma ICON -1 concentrations) and PD  markers  (including serum 
cytokine levels, circulating TF, immunophe notype patterns  and CTDNA ) analys es will be drawn 
from all study patients at pre -specified time points prior to and after administration  of ICON -1.  
For all cohorts , blood samples for PK and PD  analysis  will be collected  on Day 0  pre-injection 
and 4 hours ¬±[ADDRESS_754238] injection  (for cohort [ADDRESS_754239] injection and after the second 
injection ), and on Day 1. For cohort s [ADDRESS_754240] injection  and 4 hours ¬±[ADDRESS_754241]  injection  (for cohort [ADDRESS_754242] injection and after the second injection) , and [ADDRESS_754243] Day 7 treatment . In 
addition, for all cohorts , a blood sample for PD markers will be collected prior to enucleation  or 
plaque p lacement , as applicable .  
Blood samples for CTDNA w ill be collected along with the other PD marker samples on Day 0 
(all cohorts, pre-injection), Day 7 ( cohor ts 2 and 3 only, pre-injection) , and prior to enucleation  
or plaque p lacement  (all cohorts) . 
A PK  and PD  sample will also be obtained at the Early Termination visit if Day [ADDRESS_754244] 
Day 7 t reatment  PK/PD samples were not collected follow ing injection on Day [ADDRESS_754245] orage and handling of PK and PD  samples, 
please refer to the Laboratory  Instruction Manual  provided separately . 
15.20  Proteomic Analysis of Vitreous  
For Patients Undergoing Enucleation  Only :  Immediately f ollowing the enucleation  
procedure , vitreous humor aspi[INVESTIGATOR_574591] -1 levels  and 
proteomic analysis of TF and other cytokines , and will be sent to the central study laboratory.  
For detailed instructions regarding collection, storage, and handling of vitreous humor samples, 
please refer to the Laboratory Instruction Manual provided separately.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 61 of 86 15.21  Tumor Pathology , Genetic Profiling  and Exome Sequencing  
For Patients Undergoing Enucleation:   Following the enucleation  procedure , the eye globe 
will be sent to the local site laboratory  for pathology acco rding to the clinical site ‚Äôs standard of 
care practice . A subset of pathology slides and/or tumor block samples will be prepared by [CONTACT_574643] -related assessments, including 
ICON -1 binding to TF within the tumor, TF and PAR2 expression, characterization of the 
immune infiltrate, and alterations of the vasculature, genetic profiling (Type 1 or Type 2), and 
Exome sequencing.  Genetic profiling previously performed with fine needle aspi[INVESTIGATOR_574592].  
A central laboratory designated for the study will perform the above testing for the provided 
slides and/or tumor block samples. For detailed instructions regarding specimens preparation, 
handling and shippi[INVESTIGATOR_007], plea se refer to the Laboratory Instruction Manual provided separately.  
For Patients Undergoing Plaque Placement:   If standard of care  fine needle aspi[INVESTIGATOR_574593] , the results of that testing 
will be recorded . 
15.22  Evaluation of Adverse E vents  
Adverse events (AEs) will be monitored continuously during the study from the time that the 
subject has provided written informed consent through the subject‚Äôs last day of study 
participation. A Es may be reported spontaneously by [CONTACT_423], discovered by [CONTACT_574644], or  observed through physical examination or other means. It is 
the responsibility of the Investigator to assess and document all A Es that occur during the course 
of the study, regardless of the causal relationship with the study drug.  
The following information will be collected for all A Es and recorded on the subject‚Äôs source 
document and AE eCRF:  
ÔÇ∑ Event description (diagnosis preferred, if unknown, reco rd the signs/symptoms)  
ÔÇ∑ Onset and resolution dates  
ÔÇ∑ Severity (intensity)  
ÔÇ∑ Frequency (intermittency)  
ÔÇ∑ Relationship to study drug (causality) as determined by [CONTACT_737]  
ÔÇ∑ Seriousness  
ÔÇ∑ Action taken with study drug  
ÔÇ∑ Corrective action taken  
ÔÇ∑ Outcome  
15.22.1  Definition  of an Adverse Event  
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 62 of 86 An AE can the refore be:  
ÔÇ∑ Any unfavorable and unintended medical diagnosis, sign or symptom  
ÔÇ∑ Any new undesirable medical occurrence or unfavorable or unintended change in a pre -
existing condition that occurs during or after study treatment  
ÔÇ∑ Laboratory abnormality, vital s ign or ophthalmic assessment that is assessed as clinically 
significant and different from baseline (e.g., requiring discontinuation of study treatment, 
specific treatment, or a change in subject management). If possible, changes in laboratory 
results or c hanges in vital signs that meet the definition of an AE should be reported as a 
medical diagnosis rather than as the abnormal value (e.g., ‚Äúhypertension‚Äù rather than 
‚Äúblood pressure increased‚Äù).  
The following are special considerations when determining an d reporting A Es: 
ÔÇ∑ Whenever possible, the Investigator should group signs or symptoms that constitute a 
single diagnosis under a single AE term (e.g., ‚Äúcough, rhinitis, and sneezing‚Äù might be 
grouped together as ‚Äúupper respi[INVESTIGATOR_1092]‚Äù).  
ÔÇ∑ Pre-existing conditions are not considered A Es unless the condition worsens (increase in 
frequency, severity or specificity) during or following study drug administration. 
Fluctuations in a pre -existing condition should be assessed by [CONTACT_737], and those 
that fall within the limits of expected fluctuations for the disease state, and are not 
assessed as worsening of the disease, should not be considered A Es. Any change assessed 
as clinically significant worsening of the disease from baseline must be documen ted as an 
AE. 
ÔÇ∑ Elective surgery (including the planned enucleation surgery or brachytherapy , and 
associated inpatient hospi[INVESTIGATOR_059] , as applicable ) or routine diagnostic procedures are 
not considered A Es. However, an untoward medical event occurring durin g the pre -
scheduled elective surgery or diagnostic procedure should be recorded as an AE.  
ÔÇ∑ Death itself is not considered an AE; it is instead the outcome of an AE.  
ÔÇ∑ Pregnancy is not considered an AE, but it is an important medical event that must be 
followe d up as described in Section 15.22.8 . 
ÔÇ∑ For cohort 3, i f the IOP in the study eye following the first intravitreal injection does not 
stabilize sufficiently to the pre-injection level (i.e., within 5  mmHg of the pre -injection 
IOP) to perf orm the second intravitreal  injection , the change in IOP should be reported as 
an AE.  
ÔÇ∑ For cohort 3, e levated IOP in the study eye following the first intravitreal injection s hould 
be considered an AE if : (1) two or more follow -up IOP measurements are required to 
demonstrate stabilization to the pre -injection level (i.e., within 5 mmHg of the pre -
injection value), thereby [CONTACT_574645];  or (2) 
interventional therapy is required to return IOP to within 5 mm Hg of the pre -injection 
value.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 63 of 86 A treatment -emergent AE (TEAE) is any AE with an onset from any time after the patient  has 
received study drug  through [ADDRESS_754246] dose of study drug , whether or not it is 
considered causally related to the study drug.   
15.22.2  Serious Adverse Event  
All A Es will be assessed as either serious or non -serious. A serious adverse event (SAE) is any 
event that results in any of the following outcomes:  
ÔÇ∑ Death  
ÔÇ∑ Life-threatening (i.e., if in the view of the Investigator or Sponsor, the event‚Äôs occurrence 
placed the subject at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death if it were more severe).  
ÔÇ∑ Requires inpatient hospi[INVESTIGATOR_1081]. 
(Hospi[INVESTIGATOR_22215] a pre -existing condition or for surgery planned 
before study entry is not considered an SAE.)  
ÔÇ∑ A persistent or significant disability /incapacity (permanent or substantial disruption of the 
subject‚Äôs ability to perform normal life functions). This definition is not intended to 
include experiences of relatively minor or temporary medical significance.  
ÔÇ∑ Congenital anomaly/birth defect (an A E that occurs in the child or fetus of a subject 
exposed to study drug prior to conception or during pregnancy).  
Important medical event or serious medical condition that does not meet any of the above criteria 
may be considered an SAE if, based upon appro priate medical judgment, it may jeopardize the 
subject or may require medical or surgical intervention to prevent one of the outcomes listed 
above. Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
15.22.3  AE Severity  
The severity of an AE should be determined by [CONTACT_574646] (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) Version 4.03 (June 14, 2010)  Eye Disorders section . 
Table 3:  CTCAE Grading  
Grade 1 Mild; asymptomatic or mild symptoms; clinical or dia gnostic observations 
only; intervention not indicated.  
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL*.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 64 of 86 Grade 3  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; 
limiting self care ADL**.  
Grade 4  Life-threatening consequences; urgent intervention indicated.  
Grade 5  Death related to AE.  
 
Activities of Daily Living (ADL)  
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc.  
**Self care ADL refer to bathing, dressing and undressing, feeding self, usin g the toilet, taking 
medications, and not bedridden  
15.22.4  Study Drug Causality  
The Investigator will assess the relationship of the AE to the study drug as either ‚ÄúRelated‚Äù or 
‚ÄúNot Related‚Äù. The following should be taken into consideration when assessing SAE ca usality:  
ÔÇ∑ Positive temporal relationship to study drug, such as if the study drug was withdrawn and 
the AE resolved or the event recurred after re -introduction.  
ÔÇ∑ If there is a reasonable possibility that the AE is associated with an underlying or 
concomitant  illness.  
ÔÇ∑ Possible association with previous or concomitant therapy.  
ÔÇ∑ No temporal relationship to the study drug and/or a more likely alternative etiology 
exists.  
ÔÇ∑ If the AE is directly related to study procedures or lack of efficacy.  
15.22.[ADDRESS_754247] (AESIs)  
AESIs  are events of medical and scientific concern specific to the investigational product, for 
which ongoing monitoring and rapid communications by [CONTACT_574647] y Review Committee is appropriate. Ocular adve rse events that qualify as an AESI (even if 
non-serious) include the following:  
ÔÇ∑ Ocular inflammatory event of CTCAE  Grade ‚â• 3  
ÔÇ∑ Vitreous or retinal hemorrhage event interfering with visualization of the tumor or retina 
of CTCAE Grade ‚â• 2  
ÔÇ∑ Any acute onset trea tment -emergent vision -threatening condition as assessed by [CONTACT_574648].  Clinical Study Protocol  
IT-[ADDRESS_754248] at each 
scheduled or unscheduled study visit. At each visit, study personnel should ask the following 
question: ‚ÄúHave you had any problems since your last visit?‚Äù A Es may also be detected when 
they are volunteered by [CONTACT_574649], 
or other assessments. All A Es (serious and non -serious) reported by [CONTACT_574650] a qualified physician participating in the study and must be recorded on the subject‚Äôs source 
documents and AE eCRF.  
An AE that is classified as ‚Äúserious‚Äù requires expeditious handling and reporting to the Sponsor 
or designee within [ADDRESS_754249] be reported immediately to the 
Sponsor or designee by [CONTACT_246955] /AES I information directly into the electronic data 
capture (EDC) system (AE eCRF)  within [ADDRESS_754250] also be 
reported to the Sponsor or designee within 24 hours after the Investigator‚Äôs awareness of the 
event.  
Investigators should not wait to receive additional information to fully d ocument an SAE before 
reporting the event to the Sponsor  or designee . If only limited information is initially available, 
follow -up information regarding the SAE is  required. Additional relevant information such as 
hospi[INVESTIGATOR_1097], laboratory test results , discharge summaries  and/or autopsy reports should be 
provided as soon as these are available.  These  SAE follow -up documents should  be uploaded 
into the EDC system for informational purposes; however, if a document  cannot be uploaded , it 
should be submitt ed to  Iconic Therapeutics Drug Safety : 
Safety  Notification  
Email:  [EMAIL_10969]   
Fax:  650 -246-9011  
(or email or fax number provided on Safety Notification Cover Sheet ) 
 
15.22.7  Reporting Serious Adverse Events to Regulatory Agencies  
An AE, whether serious or non -serious, is considered ‚Äúunexpected‚Äù if the event is not reported in 
the clinical safety section of the reference document (e.g., Investigator Brochure or Package 
Insert) or if the event is of greater severity or frequency than is reported in the reference 
document.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 66 of 86 Expedited SAE reports are those SAEs that are both unexpected based on the reference 
document and considered related to the study drug (i.e., the relationship c annot be ruled out). 
The Sponsor will determine which SAEs qualify for expedited reporting.  
Reports of those SAEs that qualify for expedited reporting submitted to regulatory agencies in 
accordance with applicable local regulation (e.g., 21 Code of Federa l Regulations [CFR] 312.32 
and, as applicable, European Union Directive 2001/83/EC and 2001/20/EC).  
Expedited reports will be also distributed to Investigators. Upon receiving such notices, the 
Investigator must review and retain the notice with the Investigator Brochure and immediately 
submit a copy of this information to the governing IRB/IEC in accordance with institutional 
guidelines and local regulations.  
15.22.[ADDRESS_754251]‚Äôs last administration of study drug, and that becomes known to 
the Investigator, must be reported to the Sponsor even if the subject is withdrawn from study.  
If a subject or Investigator suspects that a subjec t may be pregnant prior to study drug 
administration, the study drug administration must be withheld until the results of blood serum 
pregnancy tests are available. If pregnancy is confirmed, the subject must not receive the study 
drug and must not be enro lled in the study. If pregnancy is suspected while the subject is 
receiving study treatment, the study drug must be withheld immediately until the result of a 
pregnancy testing is known. If pregnancy is confirmed, the study drug will be permanently 
discont inued and the subject withdrawn from the study. The Investigator must follow the 
pregnancy to conclusion, and collect data on both maternal and fetal outcome including follow -
up information regarding the course of the pregnancy and perinatal and neonatal o utcomes.  
A Pregnancy Report form will be submitted to the Sponsor, at a minimum, initially and at the 
end of the pregnancy. The Investigator is also encouraged to submit to the Sponsor trimester 
follow up reports during the pregnancy. The outcome of the p regnancy and any complications 
occurring during the pregnancy or the delivery must be reported to the Sponsor.  
A miscarriage or spontaneous abortion will be considered an SAE, and will be reported to the 
Sponsor according to the procedure described in Section 15.22.[ADDRESS_754252] and the event is determined by [CONTACT_574651], the SAE should be reported to the Sponsor and followed in accordance with the procedures 
described in this protocol.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 68 of 86 16 STUD Y ENDPOINTS  
16.1 Primary Endpoint s 
Safety  as measured by:  
ÔÇ∑ Occurrence of ocular and systemic serious adverse events and adverse events  
ÔÇ∑ Changes in standard clinical laboratory tests (serum chemistry, hematology, coagulation ) 
and ADA levels  
ÔÇ∑ Changes in vital signs and physical and ophthalmic examination s 
16.2 Secondary Endpoints  
Pharmacokinetics and Pharmacodynamic Markers  
ÔÇ∑ Plasma  levels of ICON -1 following intravitreal injections of ICON -1  
ÔÇ∑ Change in circulating TF  and serum cytokine levels followi ng intravitreal injections of  
ICON -1 
ÔÇ∑ Characterization of immunophenotypi[INVESTIGATOR_574573]  
ÔÇ∑ Change in tumor size (thickness, volume) as assessed by [CONTACT_407203] s (CFP, FA, 
sdOCT, ultrasound,  ICG angiography , EDI -OCT ) from baseline  
16.3 Exploratory Endpoints  
ÔÇ∑ Characterization of the genetic profi le of the tumor (Type 1 or Type  2), and associated 
changes in the tumor with ICON -1 treatment  
ÔÇ∑ Characterization of pathologic findings of the tumor (ICON -1 target engagement within 
the tumor, TF and PAR2 expression, characterization of immune infiltrate, and 
alterations of the vasculature)  
ÔÇ∑ ICON -1 and proteomic analysis (TF and other cytokine levels) of the vitreous humor  
 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754253] study treatment. More details will be provided in the Statistical Analysis Plan 
(SAP).  
17.[ADDRESS_754254] of the Study  
The number of patients enrol led will be tabulated by [CONTACT_574652]. Patient disposition 
(the number of subjects enrolled, treated, and completing the study) will be tabulated by [CONTACT_9084]. 
Subject discontinuations and reasons for discontinuation will be summa rized.  
17.[ADDRESS_754255] results 
(serum chemistr y, hematology, coagulation), and changes in vital signs and physical  and 
ophthalmic  examination s. Adverse events will be mapped using MedDRA.  Systemic levels of 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 70 of 86 anti-drug antibodies (ADA) during the study will be collected  for each patient. If there are 
sufficient numbers of patients exhibiting systemic levels of ADA, sum mary statistics by [CONTACT_574653].  
All collected adverse event data will be listed by [CONTACT_9084] , study site, and patient number. All 
Adverse Events of Special Interest (AESI s) occurring on or after intravitreal injection will be 
listed and summarized by [CONTACT_9084] . All adverse events occurrin g on or after treatment on Day 0  
(treatment emergent adverse events, TEAEs) will be summarized by [CONTACT_9084] . In addition, all 
serious adverse events, including deaths  (if any) , will be listed separately. Finally, all ocular 
adverse events will be listed and tabulated with events for the study and fellow eye summarized 
separately.  
Changes in laboratory data will be summarized by [CONTACT_9084] .  
17.7 Biologic al Activity Analyses 
Mean changes in tumor size and characteristics of pathologic tumor findings over time will be 
summarized  for each patient . Mean changes in BCVA, retina and tumor thickness and volume, 
and areas of vascular leakage/ exudation over time will be summarized  for each patient . 
Graphical displays of changes over time in ophthalmic ultrasound measures and ocular function 
may be constructed for each patient. Patient profiles, aggregating patient level data across many 
biological activity domains , may be used to explore joint biological effects in each patient. 
Vitreous humor (ICON -1, TF, and other cytokine levels) results over time will be summarized , if 
obtained . 
17.[ADDRESS_754256]-dose sample collected to allow estimation of the PK 
parameters.  
Individual (patient) plasma ICON -1 concentrations at each sampling time will be listed ; 
corresponding summary statistics at each sampling time will be calculated for the ICON -1. 
Plasma ICON -1 versus time profiles (with concentrations on both a log and linear scale) will be 
plotted for each patient; corresponding summary time plots will likewise be co nstructed for 
cohort .  
When applicable, p harmacokinetic parameters will be calculated using non -compartmental 
techniques from plasma ICON -1 concentrations and will include the following parameters: t 1/2, 
Cmax, Tmax, and AUC 0-‚àû. Individual ICON-[ADDRESS_754257]‚Äôs source documents (which may include medical records, hospi[INVESTIGATOR_1332], clinic 
charts/notes, diagnostics tests such as x -rays, laboratory tests and ECGs, and electronic 
recordings), and transcri bed onto electronic case report forms (eCRFs) provided by [CONTACT_1034].  
The Investigator agrees to maintain accurate source documentation as part of the case history for 
each subject. Recorded data should be updated/corrected in a manner that does not oblit erate, 
destroy, or render illegible the previous entry (e.g., by [CONTACT_740] a single line through the incorrect 
entry and writing the revision next to the corrected data). An individual who has corrected an 
entry should make clear who made the correction and when, by [CONTACT_574654]/her initials and the 
date of the correction.  
Designated site staff must complete the applicable eCRFs as soon as possible after each subject 
visit, and the eCRFs must be available for review at the next scheduled monitoring visit. 
Elect ronic case report form completion guidelines that describe how to appropriately enter data 
into eCRFs from the source documents will be provided to the study sites. If an item is not 
available or is not applicable, this should be indicated. Blank data fiel ds should not be present 
unless otherwise directed.  
Prior to locking the clinical database, the Investigator must review and approve all completed 
eCRFs to verify their accuracy.  
18.2 Monitoring of the Study  
Qualified individuals (CRAs  or Study Monitors ) design ated by [CONTACT_574655], and monitor all aspects of the study according to ICH/ GCP and standard operating 
procedures for compliance with applicable government regulations. The Principal Investigator 
(PI) agrees to allow the CRAs d irect access to study drug accountability records and drug 
supplie s, dispensing and storage areas,  clinical files of the study patients  (including original 
medical records)  and the regulatory files . The PI [INVESTIGATOR_574594]. The 
Principal Investigator [INVESTIGATOR_574595].  
The CRA will maintain necessary email, telephone, fax, and/or mail contact [CONTACT_574656] , and will visit the study sites at periodic intervals. The 
CRA will maintain current personal knowledge of the study through observation, review of study 
records and source documentation, and discussion of the con duct of the study with the 
Investigators and study site staff. During those visits, the CRA will compare the subject data 
entered in the eCRFs against original source documents at the clinical site, and evaluate the 
eCRFs for completeness and accuracy. Dat a that are modified on the eCRFs to resolve any 
discrepancies must be supported by [CONTACT_574657]. The review of subject medical records 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754258] Research Organization (CRO) 
designated by [CONTACT_1034]. All data management procedures will be detailed in separate, 
specifically identified documents that collectively will be referenced as th e Data Management 
Plan (DMP).  
The designated site personnel will transcribe the information required by [CONTACT_574658] a fully v alidated Electronic Data Capture (EDC) system 
conforming to FDA requirements for the capture of electronic data. The data will be checked for 
missing data or suspect errors upon entry against validation programs, and appropriate flags will 
be displayed on the eCRFs. The Investigator or designee will make the necessary corrections or 
verify the correctness of the data based on these flags. The database will be backed up regularly 
throughout the study by [CONTACT_574659].  
Study Monitors representing the Sponsor will review the eCRFs against the source 
documentation at the site for completeness and accuracy, and will discuss the need for further 
corrections with the Investigator or designee. In addition, computerized edit checks a nd manual 
review processes will also be performed by [CONTACT_574660].  
In order to classify adverse events and concomitant medications, preferred terms will be assigned 
to the or iginal terms entered on the eCRFs using MedDRA and WHO Drug dictionaries, 
respectively.  
After all data are entered and all data queries resolved, the Investigator must certify that the 
subject data are complete and accurate by [CONTACT_574661]. Once all eCRFs for the study are signed and the analysis populations are 
determined and documented, the clinical database will be locked.  
After the clinical database is locked, disks containing electronic copi[INVESTIGATOR_1309] a ll applicable subjects‚Äô 
eCRFs will be provided to each Investigator to be maintained on file by [CONTACT_737].  
18.4 Inspection of Records  
Investigators and institutions involved in the study will permit study -related monitoring, audits, 
IRB/IEC review, and r egulatory inspection(s) by [CONTACT_33035]. The 
Investigator or study site may be audited by [CONTACT_143294]/or regulatory 
agencies at any time. In the event of an audit, the Investigator agrees to allow the Sponsor, 
representatives of the Sponsor, the FDA, or other regulatory agency access to all study records.  
The Sponsor will review case report form data and perform electronic edit checks on the data.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-[ADDRESS_754259] charts/notes, subject medical records,  laboratory tests, and paper or electronic recordings. 
It is the responsibility of the Sponsor to inform the Investigator/institution as to when this 
documentation no longer needs to be retained.  
Records containing subject medical information must be hand led in accordance with the 
requirements of the applicable privacy rules and consistent with the terms of the subject 
authorization contained in the ICF for the study. Care should be taken to ensure that such records 
are not shared with any person or for an y purpose not contemplated by [CONTACT_9535]. Furthermore, 
eCRFs and other documents to be transferred to the Sponsor should be completed in strict 
accordance with the instructions provided by [CONTACT_1034], including the instructions regarding 
the coding of subjec t identities.  
Essential study documents should be retained until at least [ADDRESS_754260] be notified in writi ng by [CONTACT_574662]. If requested, the Investigator will provide the Sponsor, applicable 
regulatory agencies, and applicable IRB/IEC with direct access  to original source documents.  
 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 75 of 86 19 ADMINISTRATIVE C ONSIDERATIONS  
19.1 Confidentiality  
All records identifying  the patient will be kept confidential and to the extent permitted by [CONTACT_3999]/or regulations will not be made publicly available. Patient names and other 
identifying information will not be supplied by  [CONTACT_1034] . Only subject number and/o r subject 
initials will be reported in the eCRF. If the patient name [CONTACT_574671], the  information must be deleted before a copy of the 
document is supplied to the Sponsor .   
The Investig ator (or designee ) is responsible to obtain from the patient or patient‚Äôs legally 
authorized representative, written permission to use protected health information per country -
specific regulations, such as the HIPAA in the [LOCATION_002]. If permission to u se protected 
health information is withdrawn, it is the Investigator‚Äôs responsibility to document this in the 
patient‚Äôs record.  
If the results of the study are published, the subject‚Äôs identity will remain confidential. The 
Investigator is responsible for maintaining a list enabling subject‚Äôs records to be identified.  
19.2 Amendments to  the Protocol  
Any changes or deviations in the protocol will be made as an amendment to the protocol and 
approved by [CONTACT_574663]/EC before they are implemented. The Investigator  or 
designee must notify the Sponsor  or designee of any inadvertent protocol deviations upon their 
discovery, and document the deviations appropriately in the study files.  
When a protocol amendment substantially alters the study design or the p otential risks or burden 
to patients, the ICF will be amended and approved by [CONTACT_1201]/EC, and all patients on study  must 
provide new informed consent.  
19.[ADDRESS_754261]‚Äôs source 
documentation, and should be reported to the Study Monitor. Protocol deviations should also be 
reported to the site IRB/EC  in a tim ely manner and  in accordance with the policies of the 
IRB/EC.  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 76 of 86 19.4 Study Reporting Requirements  
The Investigator is responsible for submitting progress reports annually , or more frequently if 
required , to their IRB/EC and any  applicable  institutional committee s in accordance with the 
policies of their IRB/EC and institutional committees respectively. The Investigator is 
responsible for maintaining copi[INVESTIGATOR_574596]/EC 
or institutional committees . These reports must be available for review by [CONTACT_574664]. Any changes significantly affecting the conduct of the study 
and/or risk to the patients should be promptly reported to the Sponsor  its designee , the IRB/EC 
and any applicabl e institutional committees.  
19.[ADDRESS_754262] entered this study 
and for providing appropriate medical care. In addition, the Investigator  is responsible for  
managing A Es that are serious or that cause the patient to withdraw before completing the study. 
Frequency of follow -up beyond th at mandated in the protocol is left to the discretion of the 
Investigator.   
19.7 Clinical Trial Agreement  
A fully executed (signed and dated by [CONTACT_574665]) Clinical Trial Agreement describing 
the responsibilities and terms of collaboration between Iconic Therapeutics and the study site is 
required prior to initiating the study.  
19.8 Policy for Publication and P resentation of Data 
Iconic Therapeutics recognizes the importance of communicati ng medical study data and 
therefore encourages their publication i n reputable scientific journals and at seminars or 
conferenc es. The details of the processes of producing  and reviewing reports, manuscripts, and 
presentations based on the data from this study will be described in the Clinical Trial Agreement  
between Icon ic Therapeutics and the institution of the Investigator . 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 77 of 86 20 REFERENCES  
1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous 
and noncutaneous  melanoma: a summary of 84,[ADDRESS_754263] decade. The 
American College of Surgeons Commission on Cancer and the American Cancer 
Society. Cancer. 1998;83(8):1664 -78.  
2. Singh, A. D., M. E. Turell, et al.  Uveal melanoma: trends in inci dence, treatment, and 
survival.  Ophthalmol. 2011; 118(9):1881 -1885 . 
3. Shields, C. L., S. Kaliki, et al. American Joint Committee on Cancer classification of 
posterior uveal melanoma (tumor size category) predicts prognosi s in 7731 patients.  
Ophthalmol. 2013; 120(10): 2066 -2071 . 
4. Stang, A. and K. H. Jockel. Trends in the incidence of ocular melanoma i n the United 
States, 1974 -1998.  Cancer Causes Control . 2004;  15(1): 95 -96; author reply 101 -102. 
5. Stang, A., D. M. Parkin, et al. International uveal melanoma incidence trend s in view of 
a decreasing proportion  of morphological verification.  Int J Cancer . 2005; 114(1):114-
123. 
6. Virgi li, G., G. Gatta, et al. Incidenc e of uveal melanoma in Europe. Ophthalmol. 
2007; 114(12): 2309 -2315 . 
7. 28 CRN. The COMS randomized trial of iodine 125 brachytherapy for choroidal 
melanoma: V. Twelve -year mortality rates and prognostic factors: COMS report No. 28. 
Arch Ophthalmol. 2006;124(12):[ADDRESS_754264] M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, 
Hawkins BS, Hayman JA, Jaiye simi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson 
DM, Shaw JM, Straatsma BR, Thoma J. Development of metastatic disease after 
enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative 
Ocular Melanoma Study Group Report No. 26. Arch O phthalmol. 2005;123(12):[ADDRESS_754265] udy (COMS): COMS report no. 15.  
Arch Ophthalmol . 2001; 119(5):670-676. 
10. Callejo, S. A., E. Antecka, et al. Identification of circulating malignant cells and its 
correlation with prognostic factors and treatment in uveal melanoma. A prospective 
longitudinal study.  Eye (Lond) . 2007; 21(6):752-759. 
11. Battayani , Z., J. J. Grob, et al. Polymer ase chain reaction detection of circulating 
melanocytes as a prognostic ma rker in patients with melanoma.  Arch Dermatol . 
1995 ;131(4):443-447. 
12. Brossart, P.,  J. W. Schmier, et al. A polymerase chain reaction -based semiquantitative 
assessment of malignant mel anoma cells in peripheral blood.  Cancer 
Res.1995; 55(18):4065 -4068 . 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 78 of 86 13. Mellado, B. , L. Gutierrez, et al. Prognostic significance of the detection of circulating 
malignant cells by [CONTACT_922] -polymerase chain reaction in long -term 
clinically disease -free melanoma patients.  Clin Cancer Res . 1999; 5(7):1843 -1848 . 
14. Keilholz, U., P. Goldin -Lang, et al. Quantitative detection of circulating tumor cells in 
cutaneous and ocular melanoma and quality assessment by [CONTACT_5203] -time reverse 
transcrip tase-polymerase chain  reaction.  Clin Cancer Res . 2004; 10(5):1605 -1612 . 
15. Schuster, R., N . E. Bechrakis, et al. Circulating tumor cells as prognostic factor for 
distant metastases and survival in patien ts with primary uveal melanoma.  Clin Cancer 
Res. 2007; 13(4):1171 -1178 . 
16. Pi[INVESTIGATOR_57058], P., C. Mazzini, et al. Tyrosinase mRNA levels in the blood of uveal melanoma 
patients: correlation with the number of circulating tumor ce lls and tumor progression. 
Melanoma Res . 2010; 20(4):303-310. 
17. Hoon, D. S., P. Bostick, et al. Molecular marker s in blood as surrogate prognostic 
indicators of melanoma recurrence.  Cancer Res . 2000; 60(8):2253 -2257 . 
18. Van Raamsdonk CD, Griewank KG, Crosby [CONTACT_406086],  Garrido MC, Vemula S, Wiesner T, 
Obenauf AC, Wacknagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, 
Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O‚ÄôBrien J, Bastian BC. 
Mutations in GNA11 in uveal melanoma. NEJM 2010;363(23):219 . 
19. Harbour JW  et.al. Nat Genet. 2013; 45(2):133 . 
20. Sisley K  et.al.  Genes Chromosomes Cancer. 1997;19(1):22 .   
21. Onken MD  et. Al . Cancer Research 2004; 64:7205 . 
22. Harbour JW, et .al.  PloS Curr. 2013;5 . 
23. Walker TM, van Ginkel PR.; Gee RL, BS; Ahmadi H., Subramanian L,  Ksander BR, 
Meis ner LF, Albert DM, Polans AS. Factors Cyr61 and Tissue Factor in Uveal 
Melanoma . Arch Ophthalmol . 2002;120(12): 1719 . 
24. Han X, Guo B, Li Y, Zhu B.  Tissue factor in tumor microenvironment: a systematic 
review . J. Hematology & Oncology . 2014; 7:54. 
25. Sorensen BB, Rao LVM, Torneha ve D, Gammeltoft S, Petersen LC.  Antiapoptotic 
effect of Coagulation Factor Vlla.  Blood . 2003;102(5): 1708 . 
26. van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, 
Spek CA, Reits ma PH, Bogdanov VY, Versteeg HH.  Alternatively spliced tissue factor 
induces angiogenesis through integrin ligation. Proc Natl Acad Sci ([LOCATION_003]). 
2009; 106:[ZIP_CODE] .  
27. Degen JL, Palumbo JS.  Hemostatic factors, innate immunity and malignancy. Thromb 
Res. 2012;129(Suppl 1): S1. 
28. Markiewski, M. M., R . A. DeAngelis, et al. Modulation of the antitumor immune 
response by [CONTACT_30937]. Nat Immunol . 2008; 9(11): 1225 -1235 . 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 79 of 86 29. Katoh H , Watanabe M. Myeloid -Derived Suppressor Cells and Therapeutic Strategies in 
Cancer  Mediators of Inflammation .2015.  Article ID 159269.  
30. Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, et al. hI -con1, a factor 
VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous 
papi[INVESTIGATOR_10928]. Br J Cancer. 2010;103(6):812 -9.  
31. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for 
immunotherapy of human melanoma in a mouse xenograft model. Pro c Natl Acad Sci 
([LOCATION_003]). 1999;96: 8161 . 
32. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor -targeted 
immunoconjugates for ca ncer immunotherapy. PNAS. 2000;97(16): 9221 . 
33. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor 
cells for immunotherapy in mouse models of prostatic cancer  Proc Natl Acad Sci ([LOCATION_003]) 
2001; 98:[ZIP_CODE] . 
34. Hu Z., Li J. Natural killer cells are crucial for the efficacy of Icon (factor VII/human 
IgG1 Fc) immunotherapy i n human t ongue cancer. BMC Immunol. 2010; 11:49. 
35. Wang B, Chen YB, Ayalon o, Bender J, Garen A. Human single -chain Fv 
immunoconjugates targeted to melanoma -associated chondroitin sulfate proteoglycan 
mediate specific lysis of human melanoma cells by [CONTACT_574666]. 
Proc Natl Acad Sci ([LOCATION_003]). 1999;96:1627 -32. 
36. Coco E. Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, et al. Expression of 
tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: 
implications of im munotherapy with hI -con1, a factor VII -IgGFc chimeric protein 
targeting tissue factor. BMC Cancer. 2011;11:263.  
 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 80 of 86 21 APPENDICES  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 81 of 86 21.1 Appendix A:  Study Flowchart and Assessments ‚Äì Cohort 1 (Patients Undergoing Enucleation or Brachytherapy)  
Study Day  Screening1 
 
Day -7 to 0 Baseline  
Treatment  
Day 0  Day 1  NA for  
Cohort 1  Procedure 
Assessments  
(On or 1 day 
prior to Surgical 
Procedure7 day) End of 
Study  
30 days ¬±[ADDRESS_754266] 
Surgical 
Procedure  Early 
Termin -
ation  
Visit  1 2 3 42 & 52 6 7 ET 
Demographic Data  X       
Medical/Ocular/Surgical/ Medication 
History  X       
Vital Signs  X X X  X X X 
Serum Chemistry, Hematology and 
Coagulation Blood Samples  X    X X X 
Anti -drug Antibody levels (ADA)  X     X X 
Serum Pregnancy Test  
(WOCBP only)  X     X X 
Abbreviated Physical Exam X3     X X 
Best-corrected Visual Acuity by 
[CONTACT_574667]9 OU10 
Slit Lamp Biomicroscopy  OU OU SE  OU OU9 OU10 
Intraocular Pressure4 
 Pre-injection  
Post-injection(s)  OU  
OU 
SE SE  OU 
 OU9 OU10 
Dilated Ophthalmoscopy  OU SE   OU OU9 OU10 
Color Fundus Photography  OU    OU OU9 OU10 
Spectral -domain Optical Coherence 
Tomography  SE    SE SE9 SE10 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 82 of 86 Study Day  Screening1 
 
Day -7 to 0 Baseline  
Treatment  
Day 0  Day 1  NA for  
Cohort 1  Procedure 
Assessments  
(On or 1 day 
prior to Surgical 
Procedure7 day) End of 
Study  
30 days ¬±[ADDRESS_754267] 
Surgical 
Procedure  Early 
Termin -
ation  
Visit  1 2 3 42 & 52 6 7 ET 
Enhanced Depth Imaging Optical 
Coherence Tomography  
(optional according to investigator 
judgment)  SE    
SE  SE10 
Ophthalmic Ultrasound  SE    SE SE9 SE10 
Fluorescein Angiography  OU    OU  OU10 
ICG Angiography  
(optional according to investigator 
judgment)  OU    
OU  OU10 
Pharmacodynamic Assessments  
(blood sample pre and post treatment)   X5 X  X  X6 
Pharmacokinetic Assessment  
(blood sample pre and post treatment)   X5 X    X6 
Intravitreal Injection:  
COHORT 1   X   
   
Scheduled Enucleation  or Plaque 
Placement Procedure7 
(‚â•[ADDRESS_754268] of care)      
X   
Mandatory Vitreous and Tumor 
Sample  for Enucleation Patients8     X   
Adverse Events   X X  X X X 
Concomitant Medications  X X X  X X X 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 83 of 86 SE=Study Eye, OU=Both Eyes  
1 If there is study drug available at the clinical site, Screening assessments may be conducted on same day as Baseline visit ( Day 0), prior to enrollment and 
intravitreal injection. Informed consent must be obtained before  any study related screening  activity or treatment is undertaken that is not part of routine care.  
[ADDRESS_754269] Visit 4 or 5 ; the next visit after Visit [ADDRESS_754270] injection(s).   
5 Blood samples for PK and PD assessments will be drawn before and 4 hours ¬±[ADDRESS_754271] injection.  
6 At Early Termination, b lood samples for PK and PD assessments will be drawn if Day 1 PK/PD blood samples were not collected following injection on Day 0.  
[ADDRESS_754272] of care clinical management of uveal melanoma per patient‚Äôs treating physician 
and is  not a stu dy procedure.   
[ADDRESS_754273] 
procedures of the clinical site, the study -related pathology s lides  and/or tumor block sample  will be prepared and shipped to a central study laboratory for additional 
evaluations of the tumor (TF expression, ICON -1 binding, immune infiltrate, genetic profiling, and Exome sequencing). Genetic profiling of the tumor previo usly 
performed with fine needle aspi[INVESTIGATOR_574570].  
9 Ocular assessments for brachytherapy patients only.  
10 Ocular assessments at early termination visit only if early termina tion occurs prior to surgical procedure . 
  
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 84 of 86 21.2 Appendix B:  Study Flowchart and Assessments ‚Äì Cohorts 2 and 3 (Patients Undergoing Enucleation or Brachytherapy)  
Study Day  Screening1 
 
Day -7 to 0 Baseline  
Treatment  
Day 0  Day 1  Treatment  
Day 7  
¬±[ADDRESS_754274] 
Day 7 
Treatment  Procedure 
Assessments  
(On or 1 day 
prior to Surgical 
Procedure7 day) End of 
Study  
30 days ¬±[ADDRESS_754275] 
Surgical 
Procedure  Early 
Termin -
ation  
Visit  1 2 3 4 5 6 7 ET 
Demographic Data  X        
Medical/Ocular/Surgical/ 
Medication History  X        
Vital Signs  X X X X X X X X 
Serum Chemistry, Hematology and 
Coagulation Blood Samples  X   X  X X X 
Anti -drug Antibody levels (ADA)  X      X X 
Serum Pregnancy Test  
(WOCBP only)  X      X X 
Abbreviated Physical Exam X2      X X 
Best-corrected Visual Acuity by 
[CONTACT_574668]9 OU10 
Slit Lamp Biomicroscopy  OU OU SE OU SE OU OU9 OU10 
Intraocular Pressure3 
 Pre-injection  
Post-injection(s)  OU  
OU 
SE6 SE  
OU 
SE6 SE 
 OU 
 OU9 OU10 
Dilated Ophthalmoscopy  OU SE  SE  OU OU9 OU10 
Color Fundus Photography  OU     OU OU9 OU10 
Spectral -domain Optical Coherence 
Tomography  SE   SE  SE SE9 SE10 
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 85 of 86 Study Day  Screening1 
 
Day -7 to 0 Baseline  
Treatment  
Day 0  Day 1  Treatment  
Day 7  
¬±[ADDRESS_754276] 
Day 7 
Treatment  Procedure 
Assessments  
(On or 1 day 
prior to Surgical 
Procedure7 day) End of 
Study  
30 days ¬±[ADDRESS_754277] 
Surgical 
Procedure  Early 
Termin -
ation  
Visit  1 2 3 4 5 6 7 ET 
Enhanced Depth Imaging Optical 
Coherence Tomography  
(optional according to investigator 
judgment)  SE   SE  SE  SE10 
Ophthalmic Ultrasound  SE   SE  SE SE9 SE10 
Fluorescein Angiography  OU     OU  OU10 
ICG Angiography  
(optional according to investigator 
judgment)  OU     OU  OU10 
Pharmacodynamic Assessments  
(blood sample pre and post treatment)   X4 X X4 X X  X5 
Pharmacokinetic Assessment  
(blood sample pre and post treatment)   X4 X X4 X   X5 
Intravitreal Injection:  
COHORT 2   X  X     
Intravitreal Injection:  
COHORT 3   XX6  XX6     
Scheduled Enucleation or Plaque 
Placement Procedure7   
(‚â•[ADDRESS_754278] of care)        
X   
Iconic Therapeutics Inc.  Clinical Study Protocol  
IT-003 05 September 2016  
 
 
CONFIDENTIAL   Page 86 of 86 Study Day  Screening1 
 
Day -7 to 0 Baseline  
Treatment  
Day 0  Day 1  Treatment  
Day 7  
¬±[ADDRESS_754279] 
Day 7 
Treatment  Procedure 
Assessments  
(On or 1 day 
prior to Surgical 
Procedure7 day) End of 
Study  
30 days ¬±[ADDRESS_754280] 
Surgical 
Procedure  Early 
Termin -
ation  
Visit  1 2 3 4 5 6 7 ET 
Mandatory Vitreous and Tumor 
Sample  for Enucleation Patients8      X   
Adverse Events   X X X X X X X 
Concomitant Medications  X X X X X X X X 
SE=Study Eye, OU=Both Eyes , XX=two injections  
1 If there is study drug available at the clinical site, Screening assessments may be conducted on same day as Baseline visit ( Day 0), prior to enrollment and 
intravitreal injection. Informed consent must be obtained before  any study related screening activ ity or treatment is undertaken that is not part of routine care.  
[ADDRESS_754281] in jection (s).   
4 Blood samples for PK and PD assessments will be drawn before and 4 hours ¬±[ADDRESS_754282] injection (for cohort 3, after the secon d injection).  
[ADDRESS_754283] Day 7 t reatment  PK/PD blood samples were not collected 
following injection on Day 0 or Day 7.  
6 For Cohort 3 , the s tudy eye receives  two study drug  injections. The second study drug injection will occur following stabilization of IOP to within 5 mmHg of the 
pre injection measurement and ‚â•[ADDRESS_754284] of care clinical management of uveal melanoma per patient‚Äôs treating physician 
and is not a stu dy procedure.   
[ADDRESS_754285] 
procedures of the clinical site, the study -related pathology s lides and/or tumor block sample  will be prepared and shipped to a central study laboratory for additional 
evaluations of the tumor (TF expression, ICON -1 binding, immune infiltrate, genetic profiling, and Exome sequencing). Genetic profiling of the tumor previously 
performed with fine needle aspi[INVESTIGATOR_574570].  
9 Ocular assessments for brachytherapy patients only.  
10 Ocular assessments at early termination visit only if early termination occurs prior to surgical procedur e. 
 